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ABSTRACT

Does Non-Steroidal Anti-Inflannnatory Drug (NSAID) Use
Affect Dementia Progression and Survival Rates in
Alzheimer's Disease? The Cache County Study

by

Trevor Buckley, Doctor of Philosophy
Utah State University, 2011

Major Professor: Dr. JoAnn T. Tschanz
Department: Psychology

Alzheimer's disease (AD) has multiple factors that contribute to the disease
process. Among these is a state of chronic inflammation that is endured by the brain
during the aging process. The use of non-steroidal anti-inflannnatory drugs (NSAIDs)
decreases the amount of neuroinflannnation sustained by the brain, and greater levels of
NSAID use have been demonstrated to be associated with decreased probability of
developing AD. This study looked at whether greater rates ofNSAID use were also
associated with decreased rates of cognitive and functional decline and survival in a
population-based sample of persons with AD. Linear mixed models failed to find any
association between any NSAID use, duration of use, or timing of use (before or after AD
onset) and cognitive and functional outcomes. Cox regression models did not find any
association between any NSAID use, NSAID use before or after AD onset, or duration of
NSAID use and participant survival. The conclusion of this project is that NSAIDs do
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not affect AD progression or survival rates of persons with AD. These results are
discussed within the scope of the current literature.
(118 pages)
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CHAPTER I
PROBLEM STATEMENT

Alzheimer's disease (AD) is a devastating neurodegenerative disease that affects
millions of individuals worldwide. The majority of individuals with this disorder have an
onset after the age of 65, although there are early onset forms that can begin at a much
earlier age (Beyer, Lao, Laton-e, & Ariza, 2005). AD is characterized by progressive
impairment in memory and other cognitive domains, such as executive function,
attention, and language. The course of the disease is also characterized by impairments
in behavioral and functional abilities, and eventually leads to incapacity and death. There
is no treatment for AD, only palliative care for symptom reduction and management. As
one of the most common types of dementia in late-life, AD places significant economic
and emotional burden on caregivers and society. Currently, AD is the third most costly
disease in the United States, after cancer and cardiovascular disease (Ernst & Hay, 1994;
Meek, McKeithan, Schumock, & Schumock, 1998).
Reducing the prevalence of AD would decrease personal and societal burden,
because individuals with AD and their caregivers would be relieved of the great
emotional and economic costs associated with treating and managing the symptoms of
this disorder. However, because there are no available means of prevention, reducing the
degree of disability among individuals already diagnosed with AD could also have
enormous impact. Studies show that treating individuals in the early stages of AD is half
as expensive as treating individuals in the late stages of AD (Moore, Zhu, & Clipp,
2001). In addition, studies show that decreasing the rate of disease progression delays
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institutionalization and mmiality, and can increase the quality oflife in both individuals
with AD and their caregivers (Meek et al., 1998).
Research identifies several contributing factors to the etiology of AD, primarily,
the development of amyloid plaques and neurofibrillary tangles (NFT) in the brain.
Amyloid plaques are extracellular substances formed between neurons by the deposition
ofbeta-amyloid, remnants of other proteins, microglial cells, and other cellular material.
NFTs are intracellular collections of twisted proteins that affect neural microtubules, the
internal structures that maintain cellular integrity and aid in cellular transport. Together,
these two processes are hypothesized to disrupt neuronal communication and synaptic
function, and lead to neuronal death. In fact, research indicates that examining the
presence of amyloid plaques and NFT postmortem can give an accurate diagnosis of AD
85% of the time without previous knowledge of dementia status (Andreasen et al., 2001;
Hulstaert et al., 1999).
Many experimental compounds that directly target amyloid plaques and NFTs are
under development to treat or prevent AD. However, compounds that decrease the
accumulation of plaques and NFTs have only had marginal success, suggesting that there
are also other factors associated with the disease (Breitner, 1996). These therapies have
also been complicated by serious side effects such as increased risk of encephalitis and
brain hemorrhaging (Gofii & Sigurdsson, 2005). Therefore, although amyloid plaques
and NFTs are hypothesized to be the main contributing factors to AD, other treatments
targeting other causes of AD are also being pursued.
An additional contributing factor to AD pathology is neuroinflammation, the
body's natural inflammatory response to damage to the brain. Amyloid plaque
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deposition and the formation ofNFTs have been shown to trigger inflammatory
responses within the brain. Under most conditions, inflammatory responses are
beneficial, due to the activation of microglial cells that remove dead or dying neurons and
waste products that may interrupt cellular functions. However, with chronic
neuroinflammation, which is hypothesized to occur in AD, microglial response becomes
over-expressed, attacking healthy neural tissue and contributing to neurotoxicity
(Breitner, 1996; McGeer & McGeer, 2004; Walker & Lue, 2005; Wood, 2003).
Microglial overexpression is also theorized to contribute to greater tau phosphorylation,
resulting in the weakening of the microtubules within neurons and the eventual formation
of neurofibrillary tangles and cell death (Mrak & Griffin, 2005). Because it has been
shown that neuroinflammation promotes beta amyloid deposition and the formation of
NFTs, it has been theorized that reducing brain inflammation may also reduce the
neurotoxic elements that underlie AD pathology.
Non-steroidal anti-inflammatory drugs (NSAIDS) are analgesic, antiinflammatory agents that have been shown to decrease inflammation of tissue, including
tissue within the brain (Breitner, 1996; Zandi & Breitner, 2001). Because of their antiinflammatory effects in the brain, NSAIDS have been thoroughly researched as a
potential protective agent against AD. Several observational studies suggest that
NSAIDS, if taken for long enough periods of time, may be effective in decreasing rates
of incident AD (Breitner, 1996; McGeer, McGreer, Rogers, & Sibley, 1990; Stewart,
Kawas, Corrada, & Metter, 1997; Zandi & Breitner, 2001). Substantial research suggests
that the biological agents associated with AD onset, such as amyloid plaques and NFT,
are also associated with the worsening of AD symptoms, both in animal models (Murphy
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et al., 2007) and humans with AD (Augustinack, Schneider, Mandelkow, & Hyman,
2002; Haroutunian, Davies, Vianna, Buxbaum, & Purohit, 2007). Therefore, it is
plausible that NSAIDS may not only be effective at decreasing incident rates of AD, but
also at slowing the progression of AD after its onset. Factors that slow the rate of AD
progression may be helpful in reducing the severity of cognitive and functional disability,
and in promoting higher levels of functioning over the course of the illness. Although
such treatments may not lead to a cure, they may be effective in reducing the emotional
cost and burden for patients and their caregivers.
There have been few studies examining the effects ofNSAIDS on the progression
of cognitive and functional impairment in individuals diagnosed with AD. A small
number of double-blind, randomized, controlled, treatment (RCT) studies examining the
use ofNSAIDS as a treatment of AD show that treatment groups score no higher on
outcome scores of cognitive ability than placebo controls. However, an important
limitation of these studies is the short time period ofNSAID treatment, generally no
longer than one year. The duration ofNSAID use may be a critical factor, because
retrospective longitudinal studies suggest that the efficacy ofNSAIDS as a
neuroprotective agent occurs only after prolonged periods ofNSAID use (Hayden et al.,
2007). In fact, a consistent finding in the field suggests a minimum duration ofNSAID
use of two years is necessary for aneuroprotective effect (Breitner, 1996). Extrapolating
from these findings, one may hypothesize that the time requirement necessary for NSAID
use to affect the trajectory of AD progression may be just as long, if not longer. In
addition, the RCTs conducted provide no information regarding the history ofNSAID
use, once again ignoring the possibility that long exposure to NSAID use may have a
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protective effect against AD progression. Finally, these studies only examined the effect
ofNSAID use on one aspect of AD progression, cognitive decline, but did not examine
the effects ofNSAID use on other indicators of disease progression, such as functional
ability and survival duration.
In this project I examined the effects ofNSAID use on the rate of dementia
progression in a population-based sample of elderly individuals diagnosed with AD.
Specifically, I examined the effects ofNSAID use on the rate of cognitive and functional
decline and survival duration in AD. Characteristics ofNSAID use included the
initiation of use relative to dementia onset and the duration of use.
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CHAPTER II
LITERATURE REVIEW

Introduction

Alzheimer's disease is a progressive, degenerative brain disease that is
characterized by declining memory and cognitive abilities, onset of behavioral and
psychiatric symptoms, and a decline in functional abilities (Cummings, 2005). Currently,
AD is estimated to affect approximately 4.5 million individuals within the United States
(U.S.) alone, with this number estimated to rise to approximately 13.2 million by the year
2050 (Herbert, Scheer, Bienias, Bennett, & Evans, 2003). AD is the third most expensive
disease to treat in the U.S., costing the U.S. economy approximately $100 billion
annually in direct and indirect costs (Ernst & Hay, 1994). For families, the total annual
cost associated with AD is estimated at $77,000. The cost ofliving with AD is more
expensive than the costs associated with a physical disability (Schulz, Obrien, Bookwala,
& Fleissner, 1995). In the late 1990s, AD ranked fmnih among the leading causes of
death within the U.S. (Meek et al., 1998).
The social and emotional costs of AD do not solely affect individuals diagnosed
with the disorder. In recent years, research has focused on the emotional, physical, and
economic impact on individuals who care for persons with AD. Several studies have
suggested that caregivers of individuals diagnosed with AD experience more stress and
have poorer levels of overall physical health than age-matched controls (Aguglia, Onor,
Trevisiol, Saina, & Maso, 2004; Gonzalez-Salvador, Arango, Lyketsos, & Barba, 1999).
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Because the number of persons with AD increases exponentially with age, it has
been suggested that even small changes in the prevalence and incidence rates of AD can
have great impact on individuals and society as a whole (Brookmeyer, Carada, Curriero,
& Kawas, 2002). For example, it has been suggested that increasing the onset of AD by
only 5 years would decrease prevalence rates by 50% (Brookmeyer et al., 2002). In
addition, reducing the rate of cognitive decline in individuals with AD can have great
emotional and economic benefit, as individuals in the earlier stages of the disease are
more capable of carrying out basic activities of living (Ory, Hoffman, Yee, Tennstedt, &
Schultz, 1999). At least one study has shown that the costs of caring for individuals with
AD doubles from the mild to moderate stages of the disease, and once again from the
moderate to severe stages (Moore et al., 2001). One study suggests that even a small
reduction of disability could save an estimated $1,411 per year in medical costs and
$2,718 in unpaid care giving costs (Zhu et al., 2006). Clearly, the emotional, social, and
economic costs associated with AD are widespread, making the treatment and prevention
of this condition an urgent public health priority.

Contributory Factors to the Etiology of AD

Although there is no concrete evidence as to what specifically causes the
dementia in AD, three biological mechanisms have been implicated as important
contributing factors: (a) the development and accumulation ofamyloid plaques, (b) the
creation of neurofibrillary tangles (NFT), and (c) neuroinflammation. This section will
discuss how these three mechanisms contribute to AD pathology in the brain.
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Amyloid Plaques and Neurofibrillary Tangles

Amyloid plaques are nonsoluble deposits of a combination ofbeta-amyloid
protein, other unspecified proteins, and accumulated microglia. Beta-amyloid is a
protein that is cleaved from a larger protein named amyloid precursor protein (APP).
Depending on the manner in which the protein is cleaved, significant amounts of the
protein can build up over time. Studies have shown that genes involved in both the type
of APP that is generated and the type of enzymes that cleave APP can influence the
presence of amyloid plaques (Bird, 2008; Cruts & Broeckhoven, 1998). Studies have
also shown that the amyloid processes or plaques interrupt cellular communication,
which may eventually lead to neuronal cell death (Maccioni, Leonel, Fernandez, &
Kuljis, 2009).
NFTs are accumulations of protein that occur within microtubules, the cellular
structures within neurons that are responsible for the transportation of substances
necessary for cell growth, repair, and function. The microtubules within neurons are
reinforced with a special protein called tau. The strength of this protein and its ability to
stabilize microtubules rises from the number of phosphate molecules that surround it.
However, in AD abnormal amounts of phosphate molecules bind to tau, leading it to
disengage from the microtubule and bind with other tau molecules. This both weakens
microtubules within neurons and also creates abnormal accumulations of tau molecules,
which are toxic to the cell (Bramblett et al., 1993; Sengupta et al., 1998). Abnormal
phosphorylation of tau molecules has been shown to play a major role in the
accumulation ofNFTs, and compounds that inhibit this process have been shown to
decrease the amount of cellular loss in AD (Li, Liu, Barger, & Griffin, 2003b ).
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Abnormally high levels of unattached tau also inhibit axonal transport in cells, disrupting
cellular communication (Tatebayashi, Haque, Tung, Iqbal, & Grundke-Iqbal, 2004).
Together, studies have shown that amyloid plaques and NFTs are highly
diagnostic for AD, with some studies suggesting that these two biomarkers can provide a
clinically accurate diagnosis of AD 85% of the time without foreknowledge of dementia
status (Andreasen et al., 2001; Hulstaert et al., 1999). Although it is hypothesized that
these two processes contribute to the neurobiological changes involved in AD, current
research is unclear which of these two processes is primarily responsible for the
pathology of AD. Within the past several years, the question of which contributes more
to AD pathology, amyloid plaques or NFTs, has been a heated debate among researchers.
Current research suggests, however, that there is an interrelationship between the two,
with beta amyloid contributing to the accumulation of both plaques and tangles (Hardy &
Seiko, 2002). Studies have shown that this occurs because of both the direct and indirect
effects ofbeta-amyloid on tau phosphorylation and NFT fo1mation, in animal models and
research with human subjects (Lewis et al., 2001; Oddo et al., 2003). For example, in
animal models, Oddo et al. (2003) found that when a beta-amyloid antibody was
administered into the hippocampus of one hemisphere in mice, not only were beta
amyloid levels reduced, but abnormal levels of tau within the cell bodies and dendrites in
the hippocampal neurons were reduced as well. In the contra-lateral hemisphere that did
not receive the amyloid antibody, no reductions in abnormal tau levels were observed
(Oddo et al., 2003). In another study conducted by Oddo, Billings, Kesslak, Cribbs, and
LaFerla (2004), a triple transgenic model of AD was created, using mutant beta-amyloid,
presenilin-land tauP301L genes. In their model, which closely resembles the trajectory
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of AD pathology in humans, Oddo et al. (2004) discovered that beta-amyloid deposition
develops prior to the tau pathology that contributes to NFT formation.
In human subjects, studies have also found that amyloid plaques can increase tau
phosphorylation, which ultimately increases tau aggregation, mislocalization, and
accumulation (Blurton-Jones & LaFerla, 2006). As mentioned previously, tau
phosphorylation weakens neural microtubules and contributes to the creation ofNFTs. In
animal models, studies have shown that tau exposed to beta-amyloid increases its
phosphorylation both in in vitro and in vivo studies (Alvarez, Toro, Caceres, & Maccioni,
1999; Busciglio, Lorenzo, Yeh, & Yanker, 1995; Hwang et al., 2004; Puig et al., 2004;
Takashima, Noguchi, Sato, Hoshino, & Imahori, 1993). Studies have also shown that
beta-amyloid induces microglial activation and the release of inflammatory cytokines,
proteins involved in cellular communication, which also may accelerate tau pathology
and NFT formation (Li et al., 2003a; Quintanilla, Orellana, Gonzalez-Billaut, &
Maccioni, 2004; Tan, Beiser, & Vasan, 2008).
Beta-amyloid accumulation can also affect tau pathology through proteasomal
dysfunction and by disrupting axonal transport. Proteasomal dysfunction refers to the
creation of misfolded proteins through dysfunctional transcription factors, the process by
which genetic information is extracted from DNA to create the proper proteins to
synthesize materials within the body. Dysfunction of this system has been shown to play
a role in a variety of neurodegenerative conditions, such as Huntington's disease,
Amyotropic Lateral Sclerosis (ALS), Parkinson's disease, prion diseases, and AD
(Blurton-Jones & LaFerla, 2006). Proteasomal dysfunction is accelerated by betaamyloid pathology, and also contributes to the build-up of tau accumulations within
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neural cells (Blurton-Jones & Lafera!, 2006; Oddo et al., 2004). Axonal transport is the
process by which materials such as lipids, proteins, and other materials necessary for
cellular function travel to or from the body of the neuron. The process is negatively
affected by both beta-amyloid and tau accumulation (Blurton-Jones & Lafera!, 2006).
Although the degree to which beta-amyloid plaques and NFT each negatively affects
axonal transport is currently debated, recent in vivo evidence supports the hypothesis that
beta-amyloid-induced axonal transport deficits leads to the mislocalization of tau, the
prominent feature ofNFTs (Lewis et al., 2001). In addition, studies have shown that
beta-amyloid axonal transport deficits have led to increases in NFT pathology. By
contrast, axonal transport deficits caused by tau pathology have not significantly
contributed to beta-amyloid pathology (Ishihara et al., 1999; Zhang et al., 2004).

Nenroinflammation

In addition to the effects ofbeta-amyloid and tau pathology in AD, research
suggests that other factors contribute to the overall pathophysiology of AD. One
prominent process believed to contribute to neurodegeneration in AD is that of
neuroinflammation. Arnyloid plaques have been shown to trigger inflammatory
responses within the brain, including the activation of microglial cells. Microglial cells
are a type of glial cell (nonneuronal cell) within the central nervous system (CNS) that
aid in the recognition and consumption of antigens and neuronal waste products and in
repairing damaged neurons. These cells are highly abundant within the CNS, and
constitute approximately 20% of all glial cells (Wood, 2003). Under normal
circumstances, microglia functions include providing cellular maintenance and clean-up
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of cellular debris, as well as serving critical roles in defending neurons from invading
pathogens within the brain (Wood, 2003). However, substantial evidence suggests that
when the microglial response exceeds general "housekeeping" functions, and does not
return to baseline levels, chronic, excessive, and continuous microglial activity can be
toxic to the human brain. This toxicity creates a cycle that leads to a sustained, chronic
state of inflammation (McGeer & McGeer, 2004; Walker & Lue, 2005; Wood, 2003).
Studies of brain tissue from individuals with AD have shown increased rates of
microglial release and activation. For example, several studies conducted at autopsy have
discovered significantly more widespread activation of microglia in the cortical areas in
AD patients than in similar areas among normal, age-matched controls (Akiyama,
Kawamata, Dedhar, & McGreer, 1991; Arends, Duyckaerts, Rosemuller, Eikelenboom,
& Hauw, 2000; Griffin, Sheng, Roberts, & Mrak, 1995; Itagaki, McGreer, & Akiyama,

1988). Complement fragments, a prominent part of the inflammatory response cycle, are
involved in stimulating microglial release and are also found in abundance in the AD
brain, but are nonexistent in normal controls (McGeer & McGeer, 2001;
Neuroinflammation Working Group, 2000). In addition, at least one study has shown
that microglial activation in the cortex occurs early in the disease process, setting the
stage for a cascade of other events that all contribute to the neuropathology seen in AD
(Cagnin et al., 2001). The heightened activity ofmicroglia is toxic to the human brain,
the mechanism of which is hypothesized to occur through one of three primary processes:
(a) increased beta-amyloid and tau depositions through the production of additional APP,
(b) oxidative stress, and (c) rnicroglial effect on contributory cellular processes.
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Many researchers hypothesize that sustained microglial activation is an essential
element to the progressive pathological cascade of plaque formation (Griffin et al., 1995).
This is thought to occur through the genesis of additional APP. As discussed previously,
beta-amyloid is cleaved from a larger protein called APP, and greater amounts of APP
within the CNS may ultimately contribute to higher levels ofbeta-amyloid plaques
(Frackowiak et al., 1992; Mackenzie, Hau, & Munoz, 1995). Studies have shown that
microglial activation is a major source of APP production and release, which in tum may
contribute to greater amyloid plaque formation (Frackowiak et al., 1992; Mackenzie et
al., 1995; Perlmutter, Barron, & Chui, 1990).
Compounds that inhibit microglial activation have been found to be moderately
effective in reducing the amyloid plaques and NFTs found in animal models of AD, thus
providing evidence of the interactions between microglial activity and AD lesions
(Hensley et al., 2000; Mogi et al., 2000; Pulliam et al., 2001; Tikka, Fiebich, Goldsteins,
Keinanen, & Koistinaho, 200 I). Microglial release and other neuroinflammatory
processes are also associated with increased tau phosphorylation, which contributes to
NFT formation in AD (Mrak & Griffin, 2005).
Neuroinflannnation has also been shown to contribute to AD pathology through
excessive generation of oxidative stress (McGeer & McGeer, 2004). Oxidation is the
natural outcome that occurs in the human body through the process of oxygen and
cellular metabolism. However, when this natural process occurs at abnormally high
levels, or is not able to be neutralized by other substances, it becomes toxic to the brain
and other organs via the creation of oxygen free radicals. Oxidative stress has been
shown by multiple studies to be a contributing factor to the cellular processes that
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contribute to AD pathology (Banat, Gehrmann, Schubert, & Kreutzberg, 1993; Colton &
Gilbert, 1987; Corradin, Manuel, Donini, Quattrocchi, & Ricciardi-Castagnoli, 1993).
Microglia activation contributes to excessive oxidative stress; in fact, the activation of
microglia is among the primary sources of free radical production in the CNS (McGeer &
McGeer, 2004).
Lastly, one additional mechanism by which neuroinflarnmation contributes to the
pathology of AD is through the Classical Complement Pathway (CCP). The CCP is the
part of the body's immune system that is designed to identify, destroy, and relieve the
body of foreign substances, and does so by releasing the biological agents responsible for
destroying foreign material. However, one problem with CCP activation is that if host
cells have insufficient protection against the agents released by the CCP, then damage
may come to that host cell through a process called "bystander lysis."
The CCP is activated as part of the neurophysiological response to the deposition
ofbeta-amyloid protein and plaques. Normally the CCP would consume invading
organisms, however, because there are no foreign substances to consume, the agents
released by the CCP begin to attack the host neuron, which leads to cellular damage and
death (McGeer & McGeer, 2004).
The process by which amyloid plaques, NFT, and neuroinflammation contribute
to AD pathology is complex. Figure 1 depicts the dynamics of these three elements, and
how together they contribute to create AD pathology.

Nonsteroidal Anti-Inflammatory Drugs
(NAIDS) and AD Prevention
NSAIDS are medications that have analgesic and anti-inflammatory effects on the
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Initial Events
(genetic
factors/oxidative stress,
trauma)

Increased AB
production

Tangles/cell damage

Complement
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Microglial activation

Productionof toxic
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complementproducts

Loss of synapses/ neuronal
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Figure 1. The hypothetical interactions of inflammatory-associated events in the
causation of Alzheimer's disease (complement and microglial activation represent
inflammatory processes (reproduced with permission from Humana Press Publishers;
Wood, 2003).
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human body, and are the most frequently prescribed drugs for treating fever, pain, and
inflammation (Gasparini, Ongini, & Wenk, 2004; Kelley, Harris, Ruddy, & Sledge,
1989). Studies have shown that these drugs reduce the body's natural inflammatory
response in a variety of different ways. One of the primary ways in which NSAIDS
reduce inflammation is by blocking the cyclooxygenase (COX) enzyme, which is the
primary regulatory enzyme ofproinflammatory systems within the body (Gasparini et al.,
2004; Vane, 1971). There are several different COX enzymes within the human body,
with COX-I being the primary agent involved in normal "housekeeping" activities (i.e.,
cellular nutrition, clean-up of cellular debris), and COX-2 being the primary agent
involved in phagocytotic and repair functions (Gasparini et al., 2004).
Studies of human brain tissue show that when COX enzyme expression is
blocked, the neuroinflammation associated with brain injury is reduced (Halliday,
Robinson, Shepherd, & Kril, 2000; Sairanen, Ristimaki, & Karjalainen-Lindsberg, 1998).
There is also considerable evidence from both in vivo and in vitro studies that suggests
NSAIDS decrease the inflammatory responses induced by glial cells and microglial
activation, both potent contributors to AD pathology (see Halliday et al., 2000 for
complete review). Evidence from animal studies also suggests that NSAID use may
inhibit the inflammatory responses that are specifically associated with amyloid plaques
and beta-amyloid deposition, which, as discussed previously, contribute to the chronic
inflammatory response seen in AD (Netland, Newton, Majocha, & Tate, 1998; Scali et
al., 2000).
Because of the suppressing effects NSAIDS have on neuroinflammation, and the
effect that neuroinflammation has on the aging brain, it has been hypothesized that
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NSAIDS may have preventative effects on diseases such as AD. This hypothesis arose
largely due to early findings that suggested that individuals diagnosed with rheumatoid
arthritis (RA) had lower rates of AD and other types of dementia than individuals without
RA. RA is an autoimmune disease in which the body's immune system attacks the joints
of the body causing inflammation and pain. To help alleviate the pain and inflammation
associated with RA, anti-inflammatory agents are often prescribed and taken for
prolonged periods of time (Kelley et al., 1989). Retrospective observational studies have
shown that RA patients treated with NSAIDs for long periods of time have a decreased
risk of developing AD, and that concordance rates between RA and AD diagnosis are
lower than one would expect for the two individual probabilities of each disease
occurring separately. For example, in a group of7,490 discharged elderly patients,
McGeer et al. (1990) found that the co-morbidity of AD and RA was only .039%.
According to Breitner (1996), this is approximately 6 to 10 times lower than what one
would expect from the individual incidence rates of the two diseases. Additionally,
within their study, 6 of the 22 participants(> 25%) who were diagnosed with both AD
and RA were only diagnosed with AD several years after having discontinued their
NSAID use. According to McGeer et al. (1990), this likely gave additional time for AD
related neuropathology, promoted by inflammation, to take effect. Also, among the 22
individuals diagnosed with AD and RA, 21 of the 22 (>95%) all had a history of NS AID
use (McGeer et al., 1990). This raised the possibility that the unexpectedly low
concordance rates for AD and RA may be due to the long and persistent exposure to
NSAIDS among individuals with RA (McGeer et al., 1990).
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In addition, in a review of 17 epidemiological studies in nine different countries,
McGeer, Schulzer, and McGreer (1996) examined the relationship between arthritis, antiinflannnatory medication use, and AD. They concluded that NSAID use may have a
protective effect against developing AD. Specifically, they reviewed 14 case-control
studies, and found that the average odds ratio for AD associated with NSAID treatment
was 0.569 (p < .05), suggesting that individuals taking NSAID medications were
approximately 50% less likely to develop AD than individuals not taking NSAID
medication (McGeer et al., 1996). In their review, McGeer et al. (1996) also discussed
three population-based studies, the results of which "strongly supported the results of
case-control studies."
The purported link between NSAID use and prevention of AD has been
extensively studied, with the vast majority of studies concluding that NSAIDs are
effective at delaying or preventing AD. Etminan, Gill, and Samii (2003), systematically
reviewed nine studies, with over 14,500 subjects (six cohort studies and tln-ee casecontrol studies), that examined the effects ofNSAID use on specific AD diagnosis (other
forms of dementia were excluded). In their review, Etminan and colleagues found that
NSAID users were less likely to be diagnosed than non-NSAID users, but only ifNSAID
use was greater than 2 years. In another study, Szekely and colleagues (2004) conducted
a meta-analytic review ofNSAID use and development of AD. The results were largely
consistent with those reviewed by Etminan et al. (2003). Their study revealed an odds
ratio of0.51 (95% CI= 0.40-0.66,p < 0.001) for developing AD in retrospective studies,
and a Relative Risk Ratio (RRR) of0.42 (95% CI= 0.26-0.66,p < 0.001) in prospective
studies, but once again only ifNSAID use was greater than 2 years. This suggested that
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in both types of studies, individuals who used NSAIDs longer than 2 years were
approximately 50% less likely to develop AD than nonusers. More recently, in a review
conducted by De Craen, Gussekloo, Vrijsen, and Westenorp (2005), NSAID use also was
found to significantly prevent AD. However, in their review, de Craen and colleagues
found differences between the RRRs between prevalent and incident cases of AD (0.51
and 0.79, respectively), a reduction ofrisk of 50% in prevalent samples but only 20% in
incident samples. De Craen and colleagues concluded that these differences may be
partly due to recall and prescription bias in those with prevalent AD. However, they
offered no evidence regarding the disparity between subject and informant reports of
medication use, nor regarding NSAID termination in individuals with AD opposed to
individuals without AD. In addition, many of the studies reviewed relied on surrogate
informants and the direct examination of medicine containers and medical records in the
data-gathering process, therefore decreasing the extent to which the study results may be
due to recall bias (Szekely et al., 2008). Finally, in this review, AD was not the only
dependent variable examined. In 6 of the 21 studies surveyed, over 25% of the cases
were diagnosed with some other form of dementia. This inclusion criterion differs from
other studies that only examined AD. Studies have shown that different types of
dementia may differ significantly in neuropathology, trajectory, and causes (Amar &
Wilcock, 1996); thus, the effects ofNSAIDS in dementia may differ by dementia type.
In summary, the results of studies examining the relationship between NSAID use
and AD strongly suggest that NSAID use has at least some prophylactic effect on AD
(In't Veld, Ruitenburg, & Hofman, 2001; Jonker, Comijs, & Smit, 2003; McGeer &
McGeer, 2004). Research has also suggested that there are other factors to consider when
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interpreting the relationship between NSAID use and AD. One of the most important
factors to consider in the relationship between these two variables appears to be the
duration ofNSAID use. As can be seen from the literature presented above, the majority
of studies report greater reduction in AD risks for individuals who have consistently
taken NSAIDS for at least 2 years. In addition, in an editorial composed by Breitner and
Zandi (2001 ), they claim that there is also a general consensus in the field that NS AID
exposure of at least two years is necessary for the prophylactic effects ofNSAIDS on
AD. Another important factor to consider is the type ofNSAID used and the specific
geneotype of individuals at risk, particularly for genes that have been associated with AD
pathology, such as apolipoprotein E (APOE), as there is some evidence that greater
benefit is seen among individual NSAID users if they are also carriers of the E4 allele at
APOE as compared to noncarriers (Szekely et al., 2008).

NSAID Use and Cognitive Decline
after the Onset of AD

Despite the theoretical basis supporting the role ofNSAIDs in reducing
neuroinflammation in AD, and research suggesting that chronic NSAID use slows
cognitive decline in elderly individuals (Fotuhi et al., 2008; Rozzini, Ferrucci, Losonczy,
Havlik, & Guralnik, 1996), few studies have been conducted examining how NSAID use
impacts the rate of dementia progression after AD onset. The results from these studies
have been mixed, and are discussed below.
In a small RCT Rogers et al. (1993) examined 28 individuals in the mild to
moderate stages of AD. They divided their sample into treatment (n = 14) and placebo
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(n = 14) groups, with the placebo group matched to the treatment group on age, gender,

and baseline cognitive testing scores. The treatment group was administered
indomethacin, three times a day. Indomethacin is an NSAID with well-documented data
for its safety and anti-inflammatory effects. The dose was based on the participant's
weight. The two groups were administered cognitive tests including the Mini-Mental
State Exam (MMSE), Alzheimer's Disease Assessment Scale (ADAS), Boston Naming
Test (BNT), and the Token Test (TK), once at study baseline before the inception of
treatment, and once again 6 months after baseline testing. Overall, the treatment group
improved in cognitive performance across the four tests an average of 1.3% (± 1.8%)
points within the 6 months of treatment, whereas the placebo group declined in
performance across the four tests at an average of 8.4% (± 2.3%), indicating that
indomethicin was effective in decreasing the amount of cognitive decline for AD
participants within their study.
In an observational study examining the effects ofNSAIDS on cognitive decline
among individuals with AD, Rich et al. (1995) examined the differences on cognitive
testing between AD patients who had (n = 32) and had not (n = 177) a prior history of
NSAID use. The two groups differed in time since diagnosis of AD, with the group of
non-NSAID users having a longer duration of AD illness than the NSAID group.
However, after controlling for the time since AD diagnosis, the NSAID group performed
better than the non-NSAID group on MMSE scores (p = .01), BNT scores (p = .04), and
on the delayed recall portion of the Benton Visual Retention Test (BVRT;p = .02). Rich
and colleagues also examined the effects ofNSAID use on cognitive decline within their
sample by examining cognitive testing scores one year after baseline scores. After again
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co-varying for disease duration, the NSAID group showed significantly less decline on
MMSE and BNT scores, but not BVRT scores (Rich et al., 1995). The differences on
these specific neuropsychological tests are noteworthy, as MMSE scores are correlated
with AD severity, and BNT scores are a measure of confrontational naming, an ability
that declines early and precipitously in the disease trajectory of AD (Rebock, Brandt, &
Folstein, 1990).
Despite these two studies that have shown beneficial effects ofNSAID use on
cognitive decline of participants with AD, clinical trials ofNSAID medications on the
treatment of AD have failed to produce positive results. Three main RCT studies are
frequently cited within the literature that have examined the results of Rofecoxib,
Naproxen, and Diclofenac on the cognitive trajectories of individuals diagnosed with AD.
In the first, Reines et al. (2004) examined the effects ofRofecoxib on 692 individuals
diagnosed with mild to moderate AD in a one-year randomized, double-blinded,
controlled study. In their study, the treatment group received 25 milligrams ofRofecoxib
and the control group received a placebo. Rofecoxib is an anti-inflammatory medication
that selectively inhibits the COX-2 prostaglandins responsible for pain and inflammation,
as opposed to traditional NSAIDS that also block COX-I prostaglandins. The resulting
difference of effects is that COX-2 inhibitors are purported to lack the gastrointestinal
side-effects associated with traditional NSAIDS (Reines et al., 2004). This is of clinical
value because past studies have demonstrated that such side effects have contributed to
high drop-out rates in RCTs examining NSAID use and rate of cognitive decline in AD
(Reines et al., 2004). Study participants were assessed using the cognitive subscale of the
AD assessment scale (ADAS-cog) and the Clinician's Interview Based Impression of

23
Change with caregiver input (CIBIC+). Both instruments are routinely used in the
assessment of AD and AD progression in clinical trials (Reines et al., 2004). The
participants were given each test at baseline and once again after 12 months of drug or
placebo treatment. Following the 12 months of treatment, the results of their study
revealed no significant differences on either the ADAS-cog or CIBIC+ between the
treatment and control groups.
In a study conducted by Aisen et al. (2003), the effects ofRofecoxib and
Naproxen on cognitive decline were examined within a sample of subjects with mild to
moderate AD. In their study, the overall sample (n = 351) was divided into three groups
that consisted of one group being treated with Rofecoxib, one group being treated with
Naproxen, and one group receiving a placebo. While both Naproxen and Rofecoxib are
categorized as NSAIDs, Naproxen falls within the category of a "traditional NSAID" and
therefore its use may be associated with the gastrointestinal side effects of other
traditional NSAIDs. Similar to the study conducted by Reines and colleagues described
previously, each group was administered the ADAS-cog once at baseline and again after
a I-year treatment period. Their results suggested that neither Rofecoxib nor Naproxen
had any significant effects on cognitive decline compared to the placebo group over a 1year treatment period (Aisen et al., 2003).
In a study conducted by Scharf, Mander, U goni, Vajda, and Christophidis (1999),
the effects ofDiclofenac were examined on AD progression in a group of 41 patients
with mild to moderate AD. Diclofenac is also categorized as a "traditional" NSAID,
similar to Naproxen, and inhibits both COX I and II. Similar to the outcome studies
discussed above, Diclofenac did not significantly alter the course of cognitive decline in a
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sample of individuals diagnosed with AD following 6 months ofNSAID treatment
(Scharf et al., 1999). It is important to note, however, that Scharf and colleagues did note
a nonsignificant trend in the placebo group to perform worse on objective measures of
cognitive ability compared to the treatment group. In fact, Scharf and colleagues argued
that perhaps with a larger sample, significant values could have been obtained, and that
further studies with larger sample sizes and greater power are warranted (Scharf et al.,
1999).
Although the studies described above have not shown beneficial effects of
NSAID medication on the trajectory of cognitive decline in AD, there are several
limitations that warrant discussion. One main criticism is the short time period in which
the studies were carried out. As discussed earlier, research on the prophylactic effects of
NSAIDS on AD suggest that NSAIDS are only effective if taken for extended periods of
time. In fact, as mentioned previously, several studies and researchers within the field
suggest that the beneficial effects ofNSAIDS on delaying the progression of AD
pathology only occurs if the medications are taken for at least 2 years (Breitner & Zandi,
2001). In addition, current research suggests that the beneficial effects ofNSAIDS on
postponing AD may only occur early in the disease process, or before the onset of
cognitive symptoms. Although it is difficult to ascertain when the pathology of AD
begins (mounting research suggests that AD pathology may begin much earlier in life
than the onset of AD symptoms; Reiman, 2007), it has been hypothesized that there is a
purported "critical window" in which NSAIDS must be taken in order to delay or prevent
the symptoms of AD from occurring (Zandi & Breitner, 200 I). This critical window is
hypothesized to exist in the latent stages of the disease, where, although the pathology of
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AD may have already begun, the damage in the brain is insufficient to produce the actual
cognitive symptoms associated with AD (Zandi & Breitner, 2001). If this hypothesis
proposed by Zandi and Breitner is correct, then the clinical trials discussed above would
not be expected to reduce the cognitive deterioration seen in AD because the pathology
associated with the disease has progressed beyond the point where intervention can make
a difference. It may be that for a beneficial effect of NSAIDs to be seen after the onset
of AD requires an initiation ofNSAID use before dementia criteria are met and continued

for a duration of use of at least two years. Therefore, as proposed by Breitner and Zandi
(2001), future studies examining the effects ofNSAID use on AD progression should
also interact NSAID use with age to examine any interactive effect between these two
variables. In addition, as research has shown, the presence of the APOE 1:4allele may
modify the effect ofNSAID use on AD progression (Szekely et al., 2008).
In summary, research suggests that delaying the progression of AD has many
social, emotional, and economic benefits. One potential treatment to slow the
progression of AD may be NSAID use. Several studies have been conducted examining
the effects ofNSAID use on the cognitive trajectory of AD, and have provided mixed
results. These studies, however, may not have examined important variables, such as the
initiation of use, duration of use, and the possible moderating effects of APOE genotype.
In addition, studies examining the effects ofNSAID use on AD progression have focused
solely on cognitive decline, and have not considered other variables involved in the
progression of AD, such as functional ability or survival duration.

In this study I will examine the relationship between NSAID use and dementia
progression in individuals with AD. I will specifically examine whether initiation and
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duration ofNSAID use affect the rate of cognitive and functional decline and survival
duration after the onset of dementia. Specific research questions are listed below:
1. Does any NSAID use taken during the course of dementia affect the rate of
cognitive and functional decline and survival duration of individuals with AD?
2.

Does the initiation ofNSAID use, before or after dementia diagnosis, affect

rate of cognitive and functional decline and survival duration in individuals with AD?
3.

Does the duration ofNSAID use affect the rate of cognitive and functional

decline and survival duration in individuals with AD?
4.

Is there any evidence of APOE e4 interaction with NSAID use on the rate of

cognitive and functional decline and survival duration among individuals with AD?
5. For each of the research questions above, I will test for potential confounding
factors, including age, duration of dementia, and gender. Furthermore, if the NSAID use
affects the rate of dementia progression and survival duration, I will conduct an analysis
with control medications ( compounds taken for similar reasons of anti-inflammatory
effects but that lack this property), to rule out the effects of other factors associated with
the use of pain medications.
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CHAPTER III
METHODS

This project will utilize data from the Cache County Study on Memory, Health,
and Aging (CCSMHA), a longitudinal population study on the memory, health, and aging
process of elderly individuals residing in Cache County, Utah. The data to be used in this
project consist of individuals with AD identified over four waves of dementia screening
and assessment, and subsequent follow-up for up to 5 years in the Dementia Progression
Study (DPS) from the CCSMHA. In this section, I will provide a broad overview of the
study, providing information on the protocol used for identifying individuals with
dementia.

CCSMHA Dementia Screening and Assessment

The CCSMHA has been ongoing since 1995, and has completed four waves of
dementia screening and assessment, completed approximately every 3-4 years. In Wave
1, resident individuals residing in Cache County, Utah, aged 65 and older as of January
1'\ 1995 (N = 5,677; Breitner, 1996) were invited to undergo a multistage dementia
screening and assessment protocol. Study participants were also asked about their
medicine use and medical history. Cognitive screening consisted of a revised version of
the Modified Mini-Mental State Exam (3MS; Teng & Chui, 1987). Individuals whose
sensory and education adjusted screening scores fell below 87 out of I 00, or who were
selected as a "designated" subsample to complete all stages of screening and assessment,
were then studied further using the Dementia Questionnaire (DQ), an informant-based
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interview (Silverman, Breitner, Mohs, & Davis, 1986). The designated subsample was
sampled according to an iterative process to match each identified case of AD according
to age, gender, and APOE genotype. The results of the DQ were rated by a
neuropsychologist in consultation with a senior geropsychiatrist and neuropsychologist.
Elderly individuals who were given the rating of "dementia" or "significant cognitive
decline" were then invited to undergo a comprehensive clinical assessment, conducted by
a research nurse and neuropsychological technician. The nurse and neuropsychological
technician administered a battery of neuropsychological tests and neurological exams that
included the Consortium to Establish a Registry for AD (CERAD), a frequently utilized
neuropsychological battery in assessing progression of AD within the elderly.
Additionally, an informant named by the participant completed the Dementia Severity
Rating Scale (DSRS; Clark & Ewbank, 1996), which identified the participants'
competence in the major functional and cognitive domains affected by dementia.
Following the clinical visits, study participants were also administered the identical bttery
of neuropsycholgical tests in an 18-month follow-up visit.
Data collected from clinical assessment were then reviewed by a geropsychiatrist
and neuropsychologist, who assigned preliminary diagnoses of dementia according to
Diagnostic and Statistical Manual of Mental Disorders (3rd ed.; DSM-III-R; American

Psychiatric Association, 1987) dementia criteria. Those not meeting dementia criteria
were classified with other cognitive disorders or no impairment. Subjects diagnosed with
dementia were then classified according to severity stages of dementia using the Clinical
Dementia Rating Scale (CDR; Hughes, Berg, Danziger, Coben, & Martin, 1982; Morris,
1997). Age of dementia onset was assigned based on a chronology of symptoms as the
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age at which individuals met DSM-III-R (APA, 1987) criteria for dementia.
Additionally, participants who were diagnosed with dementia or its prodrome were
invited to undergo additional laborat01y testing and neuroimaging using magnetic
resonance imaging (MRI). Those with dementia diagnosis were also invited to have a
geropsychiatric evaluation.
A final diagnosis of dementia was assigned after a review of all available
information (clinical assessment, laboratory and neuroimaging information, and
geropsychiatry evaluation) at consensus conferences consisting of experienced clinicians
in geropsychiatry, neurology, and neuropsychology. A diagnosis of AD followed the
criteria provided by the National Institute ofNeurological and Communicative Disorders
and Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA;
McKhann et al., 1984). Diagnoses of other types of dementia followed other standard
research protocol. All study procedures were identical in each wave, with the exception
of a slight modification of screening cut-off scores in Waves 2, 3, and 4, and the
elimination of the DQ in Waves 3 and 4. In these two waves, individuals who met the
cut-off criteria for the 3MS were chosen to participate in the clinical visits as described
above. Furthermore, Wave 4 MRI and laboratory testing were restricted to those whose
diagnosis of dementia-type was unclear.
Following a diagnosis of dementia, participants were then followed at a 12-18
month visit to confirm their dementia diagnosis, and subsequently on a semiannual basis
according to the protocol delineated in the DPS. The study procedures were similar to
that of the clinical assessment in which measures of medications and medical hist01y
were completed.
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Study Participants

The participants in the present project include those who were diagnosed with AD
following the CCSMHA methods as explained above. Following the first screening wave
of the CCSMHA, 356 individuals were diagnosed with dementia, and were therefore
labeled as "prevalent dementia" cases. Following Wave 2, 191 individuals were
identified with dementia. In Waves 3 and 4, 394 individuals were identified with
dementia, thus totaling 941 individuals identified with dementia following the four
screening waves of the study, 356 prevalent cases and 585 incident cases. Of the 941
individuals identified with dementia, 572 (60.7%) were diagnosed with AD. Of these,
244 cases were prevalent cases whereas 328 were incident cases. The 328 incident cases
comprise the sample ofthis study.
Study Measures

Mini-Mental State Exam

The MMSE test is often used as a screen for dementia and cognitive decline in
elderly populations. The test includes questions and problems in a number of different
areas, including psychomotor skills, memory, orientation, language use, comprehension,
and constructional praxis. The test ranges in scores from 0-30, with scores 27-30
suggesting normal functioning, 20-26 suggesting mild dementia, 10-19 moderate
dementia, and below 10 severe dementia, with low to very low scores correlating closely
with the accurate diagnoses of dementia (Folstein, Folstein, & McHugh, 1975). The test
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form used in the CCSMHA and DPS was the CERAD modified version (Welsh et al.,
2004). A copy of the MMSE can be found in Appendix A of this project.

Clinical Dementia Rating Scale (CDR)

The CDR is a scale that is used to rate dementia severity and functional outcomes
in participants with dementia (Juva et al., 2006). The scale is completed during a
semistructured interview administered by a nurse, and focuses on the participant's
functional abilities in six different areas: memory, orientation, judgment and problem
solving, community affairs, home and hobbies, and personal care. Scores in each of these
areas may be combined to obtain a composite score on a 5-point scale, with values of 0
(no cognitive impairment), 0.5 (questionable dementia), 1 (mild dementia), 2 (moderate
dementia), 3 (severe dementia), 4 (profound dementia), and 5 (terminal dementia). For
this project, I summed the scores in each domain to use as a total CDR score, referred to
as the CDR Sum of Boxes (CDR-SB) method, a method used by O'Bryant et al. (2008),
utilizing a range of scores from 0-30. A copy of the CDR can be found in Appendix B
of this project.

Survival Duration

As part of ongoing surveillance of the CCSMHA, mortality was monitored by
newspaper obituaries and by quarterly reports from the state ofUtah Department of Vital
Statistics. For each death, the date of the death was obtained, and survival duration will
be calculated from the age of dementia onset to the date of death (in years).
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Medication Qnestionnaire

During each screening wave of the CCSMHA and continued in the DPS,
participants were asked to show the interviewers all of the medications, ointments, and
nutritional supplements they were currently taking. They were then asked if they suffered
from a medical condition from a selected group of medical conditions (such as painful or
inflammatory conditions, respiratory or gastrointestinal problems, and others). They
were then asked if they used any medications that pertained to each grouped condition
from an 8 x 11 printed drug card that listed various prescription and nonprescription
medications commonly used to treat the conditions. Such questions were asked in the
form of: "Have you used any of the medications on this card regularly, that is once a
week for a month or longer, for any of the conditions that we just discussed or for any
other reason?" Reported current and past medication use was then noted for its type,
duration, amount, form, and reason for consumption in a medication booklet. Finally,
participants were then asked once again for any prescription or nonprescription drug use
for those conditions that were not listed on the 8 x 11 printed drug cards.
Type of medication use was then coded by a team of Quality Assurance (QA)
technicians, using the Mosby coding system (Mosby's, 2007). Medications that
resembled many of the effects ofNSAIDS, such as analgesia and fever-reduction
properties, but that lacked the neuroinflammatory effect ofNSAID medications, were
coded and available for use as the control group of medications in this project (i.e.,
Tylenol). The medication questionnaire was used in each wave of the CCSMHA and
each visit of the DPS.
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Coding NSAID Use
To characterize NSAID use, certain aspects of use were important to capture, such
as: (a) a participant ever using NSAIDs, (b) the initiation ofNSAID use in relation to the
onset of dementia, and (c) the duration ofNSAID use. Eve1y use ofNSAID was coded
positively if the use of any NS AID was taken for a minimum of at least once a week for a
month or longer. This threshold has been used in other work from the Cache County
Study (Hayden et al., 2007). To reflect initiation of use, I created a second variable that
reflected the timing ofNSAID use, before or after AD onset, or both before and after AD
onset. This variable had four levels: (a) individuals who had never used NSAID
medications, before or after dementia onset, (b) NSAID users prior to dementia onset
only, (c) NSAID users after dementia onset only, and (d) NSAID users both before and
after dementia onset.
Addressing issue number three required capturing NSAID exposure throughout
the lifespan to capture the duration oflifetime NSAID use. Because NSAIDs are often
taken in episodes, the age at which NSAID exposure began and the age at which NSAID
exposure ended was determined as well as the total number of episodes. Exploratory
analyses revealed that subjects often began use, stopped, and then resumed use years after
initial use. Because it was not assumed that periods of no-use could be considered
continuous, I derived the NSAID duration variable as a time-dependent variable, not a
time-continuous variable. Although there were some reports ofNSAID exposure in
childhood and adolescence, their use was excluded due to potential recall bias and
relevance to inflammatory processes in late-life. Thus, to be considered positive for
exposure required any reported NSAID use after age 45.
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Strategy to Address Inconsistent Reporting

Because of the CCMS and DPS studies queried participants and caregivers at each
wave and visit there were several opportunities for discrepant reporting due to recall bias
of start and stop dates. Such discrepancies may be frequent in longitudinal studies
(Romeo, 1997). As in other studies, several common discrepancies were noted in my
study as well. For example, in several instances, participants reported no NSAID use at
Wave l; however, at Wave 2 these participants reported NSAID use that predated Wave
1. Due to the likelihood of recall bias, the information that was given at the time of the
medication inventory was considered to be the most reliable (in this case; no NSAID use
at Wave 1). Similar situations were dealt with in the same manner. If there were
discrepancies between the information gathered at the time of the medication inventory
and the information that was obtained by recall, the information gathered at the
medication inventory was considered the most reliable and was used in this study.
In some instances, inconsistencies in reporting resulted in another problem dating
the onset ofNSAID use. If the actual date for which initiation ofNSAIDs was unknown,
such as in the case given above (no reported NSAID use at Wave 1 but reported NSAID
use at Wave 2 that predated Wave 1) then the midpoint between the interval between
Waves 1 and 2 was adopted as the start date, which was subsequently converted into the
age of use. For example, if a participant was age 76 at Wave 2, and reported NSAID use
at Wave 1 but his/her records show that at Wave 1 he/she reported no NSAID use during
this time then the midpoint between Wave 1 and 2 was taken (1.5) and deducted from
his/her Wave 2 age (76) as the age of actual age of the initiation ofNSAID use.
Therefore, in this case, the actual initiation ofNSAID use was estimated to be 74.5 years
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of age (76 - 1.5 = 74.5). This approach has been used previously in longitudinal research
methodology when there is conflicting information, or on studies of recanting behavior,
and is considered an unbiased estimate for capturing inconsistent longitudinal data
(Fendrich & Rosenbaum, 2003; Romeo, 1997). For all discrepancies of reported NSAID
use between study waves, I adopted the midpoint between study waves as the time of
NSAID onset. In the case where there was reported NSAID use at Wave 1, but the
participant did not know the beginning of the NS AID use, I calculated the weighted
average of all the time intervals between study waves (Waves 1 through 4) and divided
by two (1.8 years, or 21.68 months).

Statistical Analyses

l<·orresearch questions examining the relationship ofNSAID use to cognitive or
functional decline, I used linear mixed effects models in statistical analyses. The data
gathered in this study are longitudinal in nature, resulting in several time points of data
that are correlated. Traditional generalized linear models are not appropriate for
examining such data because they assume that all observation points are independent of
each other (Singer & Willett, 2003 ). An advantage oflinear mixed models is that they
accommodate observations that are dependent or correlated (Singer & Willett, 2003). In
addition, linear mixed effects models allow the examination of both random and fixed
effects, whereas traditional generalized linear models only allow the examination of fixed
effects (Singer & Willett, 2003). Fixed and random effects can best be explained in that
fixed effects refer to a certain option from a fixed set of options whereas random effects
refer to a certain option from an infinite array of options (Singer & Willett, 2003). In the
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present analyses, I included both fixed effects (e.g., NSAID use, covariates such as
gender) as well as random effects (e.g., time). In this case, time was treated as both a
fixed effect (to obtain effect estimates) and a random effect because the follow-up time of
each participant varied widely.
To address research question one, whether NSAID use affects AD progression, a
series of mixed effects models were conducted for two forms of dementia outcome;
MMSE and CDR-SB scores. In these models, ever/never NSAID use was the
independent variable (fixed effect ofNSAID use, with time treated as both fixed and
random). MMSE and CDR-SB scores were the dependent variables. To address research
question two, whether the timing ofNSAID use had an effect on AD progression, a series
of mixed effects models were conducted, where the initiation ofNSAID use before
dementia unset, after dementia onset, or both was the independent variable and MMSE
and CDR-SB scores were the dependent variables. Again NSAID use was treated as a
fixed effect, and time as both fixed and random effects. To address research question
three, whether the duration ofNSAID use affects AD progression, a series of mixed
effects models were fit with MMSE and CDR-SB scores serving as the dependent
variables. Duration ofNSAID use was operationalized as years of continuous use and
served as the independent variable (fixed effect). Time was treated as both a fixed and
random effect. For each of these analyses I also tested the effects of the following
covariates: gender, dementia duration, age, and education. Based on the research
conducted byBreitner and Zandi (2001), regarding age and NSAID use interaction, I also
interacted NSAID use, as defined by research questions 1-3, with participant age at AD
onset to test for possible interactive effects between these two variables.
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In addition, in order to maximize the effect oftiming and duration ofNSAID use,
I conducted the above analyses with two groups: (a) at least 2 years ofpreonset NSAID
use and at least some postonset NSAID use, and (b) no NSAID use. In these models,
NSAID use versus no use was the independent variable (fixed effect ofNSAID use, with
time treated as both fixed and random) and MMSE and CDR-SB scores were the
dependent variables.
For research question four, to examine whether the presence of APOE a4 modifies
the effects ofNSAID use on AD progression, I tested the interaction between NSAID use
and the presence or absence of APOE and its effects on AD progression using linear
mixed effects models. In this research question, NSAID use was defined as either
ever/never NSAID use, NSAID use before, after, or both before and after AD onset, and
as years of continuous use.
To examine an association between NSAID use and survival duration (or
mortality), I used survival analyses. Survival analysis examines whether the variation of
an occurrence of an event (hazard) systematically varies with a given set of predictors
(Singer & Willett, 2003). Basically, the variable of interest in a survival model is the
amount of time that passes until an event occurs (Singer & Willett, 2003). The time
variable can be expressed in years, months, and so forth, or even the age of an individual
until an event occurs. The event can be expressed as any designated experience of
interest such as death, onset of an illness or disease, end of a treatment program, and so
forth. Cox regression models (also called proportional hazards modeling) are a type of
survival analyses and are currently the most commonly methods used in the survival
analyses family (Singer & Willett, 2003). One of the reasons for its popularity is because
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it allows the use of time-dependent covariates that may change in value over the course
of the observation period (Cox & Oakes, 1984). In this project, NSAID use changed
often over the course of the study, and therefore Cox regression models were used in
analyses to answer the question of whether NSAID use affected mortality. Mortality
served as the event, and time until death served as the dependent variable. NSAID use
served as the independent variable. Hazard risk ratios (HR) were calculated to assess the
relative risk of each of the above individual variables on the mortality of participants in
the study. An HR of one can be interpreted as there is no risk difference between groups,
whereas an HR greater than one indicates a greater chance of an event in the exposed
group than in the unexposed group. An HR of less than one indicates a less likely chance
of an event in the exposed group than the unexposed group. An HR either greater than or
less than one can be subtracted from 1; the remainder (absolute value) represents the
chance of an occurrence of the event in the exposed group relative to the unexposed
group. For example, a HR of 1.45 can be interpreted as 1 - 1.45, or .45, or a 45%
increase in risk of an event in the exposed group as compared with the unexposed group.

A HR of .23 can be interpreted as 1 - .23, or .77, or a 77% decrease in risk in the exposed
group compared to the control group.
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CHAPTER IV
RESULTS

In this sample, there are significantly more female than male participants
(approximately 66%,p < .01) of the total 328 participants. The average age of the study
participants at study baseline was approximately 84 years (SD= 6.45). Participants had
an average of approximately 3 visits (3.13) following dementia diagnosis (SD= 2.47),
and an average of 13.2 years of education (SD= 3.00). Both baseline MMSE and CDRSB have ranges of one to thirty, with MMSE scores averaging 21.92 points (SD= 4.6)
and CDR-SB scores averaging 6.01 points (SD= 3.38). As mentioned previously, a
score of 21.92 points on the MMSE is interpreted as mild dementia, whereas a score of
6.01 on the CDR-SB is interpreted as mild functional impairment. The sample
characteristics are summarized in Table I.
As can be seen from Table 1, study participants did not each receive the same
amount of follow-up visits. The range of potential visits was 1-10, with the mean amount
of visits being 3.13 (SD= 2.47). The reasons for participants not receiving a follow-up
were due to incomplete visits, subject refusal, participant deceased, moved or were
temporarily out of the area, or could not be located. Any other circumstances for which
participants did not complete the visits were coded as "other." The primary reason for
loss to follow-up or drop out was mortality as illustrated in Figure 2 below.
There were 297 out of 328 participants who completed the MMSE at their
baseline visit. For those who did complete the MMSE, the majority were female (67% to
33%), had approximately 13.4 years of education, were approximately 84 years old, and
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Table I
Summary of Participant Characteristics at Baseline
Sample characteristics

Number

%

112
216

34.1 **
65.9**

128
19

39.0
5.8

265
41
22

80.8
12.5
6.7

Mean

SD

Gender
Male
Female
APOE s4 type
One allele
Two alleles
Place ofresidence

Home
Nursing facility unlocked
Skilled nursing facility
Education

328

13.20

3.00

Age at baseline

328

84.21

6.45

Dementiaduration

328

1.71

1.26

Follow-up visits

327

3.13

2.47

Baseline MMSE

297

2!.92

4.60

Baseline CDR

327

6.01

3.38

**p < .01.

at baseline, had been identified with dementia for approximately 1.71 years prior to
baseline measures. There were no significant differences in gender for those who did and
did not complete the MMSE at baseline, neither did participants who did not complete
the MMSE at baseline differ in educational attainment, T= 1.77, df= 326,p = .078, or
dementia duration at baseline, T = .0l 4, df = 326, p = .99, from those that did complete
the MMSE at baseline. However, participants who completed baseline MMSE scores
were younger at dementia onset than participants who did not complete baseline MMSE
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scores, T= -2.74, df= 326,p = .007. Participants who did not complete baseline MMSE
scores were indicative of not completing the MMSE in other study visits. Only 3 of the
31 participants who did not complete the MMSE at baseline had three or more consistent
MMSE scores at follow-up visits. Table 2 provides information regarding those who did
and did not complete the MMSE.

Cognitive Trajectory-MMSE

Those who completed the MMSE averaged approximately 21.92 points (SD=
4.60). The distribution of scores followed a normal curve for baseline scores, but
deviated from normality with an increasing number of visits (number of completed
MMSEs decreased). As the number of visits decreased, along with the number of
completed MMSE scores, distributions began to appear more bimodal in nature.
The mean MMSE scores decreased consistently throughout each visit, falling on
average .67 points between each visit (SD= 1.33). However, there was much variability
in individual trajectories on the MMSE between each visit. To illustrate this, a trajectory
Plot of individual scores on the MMSE is presented in Figure 3.

Table 2

Descriptive lriformation of MMSE Completers and Noncompleters
Sample characteristics
Gender
Male
Female
Education
Age at dementia onset
Dementia duration at baseline

**p < .01.

Complete MMSE
Number
%
Meao
98
199
297
297
297

SD

33.0**
67.0**
13.39
83.90
1.71

2.96
6.36
1.27

Did not com2Iete MMSE
Number
%
Mean SD
14
17
31
31
31

45.2
54.8
12.39
87.19
1.71

3.33
6.6
1.43
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Number of follow-up visits

Figure 3. Trajectory ofMMSE scores by visit.

Functional Trajectory--CDR-SB

Nearly all participants had CDR-SB scores at baseline, with only one participant
lacking a score. Mean CDR-SB scores at baseline were 5.98 (SD= 3.38). The
distribution of CDR-SB scores at baseline was approximately normal in shape. However,
similar to the MMSE scores, deviated from normality as visit number increased.
The mean CDR-SB scores increased consistently throughout each visit, increasing
on average .6 points between each visit (SD= 2.35). However, there was much
variability in individual trajectories on the MMSE between each visit. To illustrate this, a
trajectory plot of individual scores on the MMSE is presented in Figure 4.

Survival Duration and Mortality

As mentioned, participant mortality was determined by newspaper obituaries
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Figure 4. Trajectory of CDR-SB scores by visit.

and by quarterly reports from the state of Utah Department of Vital Statistics. From
these records, 68% (n = 223) of the 328 participants had passed away by the date of the
dataset creation (November 6, 2007). There were significantly more females than males
in both the deceased and nondeceased groups, but there were no differences between the
two groups in terms of dementia duration or level of education. Subjects who were
deceased as of November 6, 2007, were significantly older at age of dementia onset than
individuals not-deceased as of this date. Descriptive information about the deceased and
nondeceased groups can be found in Table 3.

Outline of Results

The research questions posed before the Results section indicated two different
types of questions were being asked: (a) regarding the trend of decline in cognitive and
functional ability of the participants in this study, and (b) regarding the rate of mortality
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Table 3
Descriptive Information on Participant Mortality
N ondeceased
Sample
characteristics
Nnmber
Gender
34
Male
Female
71
Time in study (in
105
years)
Education
105
Age at dementia onset
105
Dementia duration at
105
baseline
* significant at the 0.001 level.
** significant < 0.0001 level.

%

Deceased
SD

Number

%

35.0**
65.0**

4.38

2.98

78
145
222

13.30
81.42*
1.54

2.98
5.89
1.17

223
223
223

Mean

32.4**
67.6**

Mean

SD

4.43

2.53

13.15
85.42*
1.80

3.02
6.35
1.29

of participants in this study. Although the statistical analyses used to answer these
questions were different in nature, the results from each analysis will be presented in
reference to each research question. For example, for research question 1, both the
results from the linear mixed models and the Cox regression models will be presented in
order to respond to this research question. Following research questions will be answered
in a similar fashion.

Research Question 1: Does any NSAID use taken during
the course of dementia affect the rate of cognitive
and functional decline and survival duration
of individuals with AD?

Cognitive and Functional DeclineLinear mixed models
According to the criteria of ever being exposed to NSAIDs, approximately 56%
(56.4%, N = 185) of the individuals in this study had used NSAIDs at some point in their
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lives. There were significantly more females than males who used NSAIDs,

x2 = 32.05, df

=I,p < 0.001, and also more females than males in those who did not use NSAIDs,
43.54, df

x=
2

= l,p < 0.001), but there were no differences in age at baseline or education

level between users and nonusers, T= 0.364, df= 326,p

= 0.716; T= 0.374, df= 326,

p = 0.709. There were also no differences on baseline MMSE and CDR-SB scores
between NSAID users versus nonusers, T= -0.066, df= 295,p = 0.947; T= 1.174, df=

325,p = 0.241. Descriptive information on NSAID users and nonusers are displayed in
Table 4.
I also examined whether NSAID versus non-NSAID users differed in frequency
of medical comorbidities histories up until study baseline. Among these were (in order as
listed in Table 5): any history of the following; respiratory distress (asthma, frequent
bouts of pneumonia, emphysema, chronic bronchitis); cardiovascular accident (CVA) or
transient ischemic attack (TIA); myocardial infarction (MI); angioplasty; chronic pain or
inflammation (stemming from chronic headaches, chronic pain conditions, past
operations); hypertension; high cholesterol levels; diabetes; head injury (HI); cancer; and
angina. There were relatively few differences between NSAID users and nonusers on the
variety of these different medical comorbidities. Among all those listed, only
hypertension,

x = 7.15, df=l,p
2

< 0.01, and chronic pain, y!= 8.56, df=I,p < 0.01,

significantly distinguished the two groups, with having a history of chronic pain and
hypertension problems more likely in the NSAID than in the non-NSAID group.
Table 5 lists the frequencies and proportions between these two groups in terms of
the medical comorbidities discussed.
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Table 4
Descriptive Information for NSAID Users and Nonusers

SamEle characteristics
Gender
Male
Female
Age at dementia onset
Education
Baseline MMSE
Baseline CDR

Number
58
85
143
143
129
143

N o-NSAID use
%
Mean

SD

Number

6.46
3.17
4.12
3.45

54
13 I
185
185
168
184

40.6**
59.1 **
84.36
13.27
21.90
6.23

Table 5
Medical Comorbidities Between NSAJD Users and Nonusers

Auy respiratory
AuyCVA/TIA
AuyMI
Any CBG surgery
Auy angioplasty
Auypain**
Auy hypertension**
Any cholesterol
Auy diabetes
Any HI
Auy cancer
Auy angina

N
(%)

NoNSAID use
NO
YES
116
28
(80.6)
(19.4)
107
37
(74.3)
(25.7)
124
20
(86.1)
(13.9)
133
11
(92.4)
(7.6)
136
8
(94.4)
(5.6)
101
43
(70.1)
(29.9)
67
77
(46.5)
(53.5)
96
48
(66.7)
(33.3)
115
29
(79.9)
(20.1)
96
48
(66.7)
(33 .3)
142
2
(98.2)
(1.4)
139
5
(96.5)
(3.5)

NSAID use
NO
YES
151
33
(82.1)
(17.9)
134
50
(72.8)
(27.2)
153
31
(83.2)
(16.8)
175
9
(95 .1)
(4.9)
174
10
(94.6)
(5.4)
101
83
(54.9)
(45.1)
58
126
(31.5)
(68.5)
109
75
(59.2)
(40.8)
149
35
(81.0)
(19.0)
123
61
(66.8)
(33.2)
179
5
(97.3)
(2.7)
179
5
(97.3)
(2.7)

**Significant differences between NSAIDs and non-NSAID users at the .01 level.

NSA!Duse
%
Mean

SD

29.2**
70.8**
84.10
13.14
21.94
5.79

6.45
2.88
4.95
3.33
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MMSEScores

Linear mixed models demonstrated that MMSE scores significantly decreased
overtime, n = 328, T= -13.06,p < 0.001. Ever/never use of an NSAID medication was
not significantly related with subject's average MMSE scores, LRx2 = .051, df= 2,
p = 0.956, nor the rate of cognitive decline, LRx2 = 1.67, df = 4,p = 0.79. To examine
whether there may be any effect ofNSAIDs among those with mild dementia, I also
analyzed data restricted to only participants whose CDR-SB score was less than or equal
to I at the initial baseline visit. There was no effect ofNSAID use on overall MMSE
scores, LRx2 = 1.48, df= 2,p = 0.47, or rate of decline over time, LRx2 = 1.86, df= 4,
p = 0.60. The following covariates were added to the model: level of education, age at
dementia onset, dementia duration, gender, and APOE gene presence/absence. The
results showed that greater levels of education were associated with overall higher
MMSE scores, LRx2 = 6.57, df= I,p < 0.01, p = 0.23, and for those with longer
dementia duration before diagnosis had lower overall MMSE scores, LRx2 = 27.83,
df = 1,p < 0.001, p = -1.07. Females declined faster than males on MMSE scores,
LRx2 = 6.50, df= 1,p = 0.01, p = -.69. There were no significant interactions between
age of AD onset and NS AID use. In the presence of the covariates, the null findings for
NSAID use onMMSE scores remained, LRx2 = 2.86, df= 2,p = 0.29, as with rate of
cognitive decline, LRx2 = 4.10, df = 4, p = 0.35.

CDR-SB Scores

Linear Mixed Models demonstrated that CDR-SB scores significantly increased
over time, n = 328, T = 12.96, p < 0.00 I. However, linear mixed models demonstrated
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that ever/never NSAID use did not significantly affect overall CDR-SB scores, LRx2 =
0.30, df = 2,p = 0.86, nor the rate of change over time, LRx2 = 3.276, df = 4,p = 0.51.
There was also no effect ofNSAID use among the subgroup of persons starting out with
mild dementia on overall CDR-SB overall scores, CDR-SBs :S1; n = 283, LRx2 = 1.23,

df= 2,p = 0.54, nor rate of CDR-SB change over time, LRx2 = 2.33, df= 2,p = 0.32.
When adding covariates of education, age at dementia onset, dementia duration, gender,
and APOE genotype, individuals with a longer dementia duration had higher initial CDRSB scores (greater impairment) than individuals with shorter dementia duration, LRx2 =
63.73, df= l,p < 0.001,

~

= 1.09. There was also a trend for males having significantly

greater overall CDR-SB scores (greater impairment) than females, LRx2 = 3.642, df= l,

p = 0.055,

~

= 0.70. Age interactions with NSAID use showed no significant differences

in overall CDR-SB scores, LRx2 = 2.87, df= 2,p = 0.23, nor rates of CDR-SB increase
throughout study visits, LRx2 = 1.42, df= 4,p = 0.84.
Cox Regression (Mortality). To examine the relationship between any NS AID

use and mortality, I plotted mortality and its relationship to timing of visit using a
Kaplan-Meier plot. As displayed in Figure 5, there is very little separation between
survival curves for those with versus without NSAID use. Additionally, the estimated
median between the two groups (NSAID use vs. no NSAID use) on length of survival
time did not appear to contain any significant differences (median ofNSAID group =
5.522 [standard error= .282[, median ofno NSAID group= 5.502 [standard error=
.289]). A log rank test showed no significant relationship between the survival times of
subjects with NSAID and no NSAID use, x2 = 0.013, df = l,p = 0.91.
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Figure 5. Kaplan Meier plot of ever/never NSAID use.

The results of the Cox Regression model were similar to linear mixed model
results. Any NSAID use, regardless of length of use or timing of use, was not
significantly associated with mortality (Hazard Ratio [HR]= 1.023, df= l,p = 0.867,
CI= .78, 1.34. When including the covariates education, age at baseline, gender and
APOE genotype, earlier onset age of dementia was associated with shorter survival
duration (HR= 1.09, df = I,p < 0.001, CI= 1.07, 1.12), as did male gender (HR= 1.436,

df= l,p = .01, CI= 1.08, 1.91).
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Research Question 2: Does the initiation of NSAID use, before
or after dementia diagnosis, affect the rate of cognitive
and functional decline and survival duration in
individuals with AD?

For NSAID use before, after, and both before and after AD diagnosis I created a
variable reflecting four mutually exclusive groups: (a) subjects who had never taken
NSAIDs, (b) subjects who had NSAID use only prior to AD diagnosis, (c) subjects who
had NSAID use only following AD diagnosis, and (d) individuals who had NSAID use

both pre- and post-AD diagnosis. When dividing NSAID use into these four separate
categories, 44% (43.6%, n = 143) had never used NSAIDs at any point in their lives.
Fifty-seven individuals (17.4%) used NSAIDS prior to their AD onset only, while 32
individuals (9.8%) used NSAID medications following AD onset only. Ninety-six
individuals (29.2%) had used NSAIDs both prior to and after AD onset. There were
significantly more females than males in tluee of the four levels ofNSAID exposure: (a)
no NSAID use ever, n = 143, x'= 5.44,p = 0.02, (b) NSAID use before AD onset only,

n = 57, x'= 7.737,p = 0.005, and (c) NSAID use both pre- and post-AD onset, n= 96,

x' = 27.38,p

< 0.00. There were no significant differences in proportion of males and

females in the third group, NSAID use following AD onset, n = 32, x'= .5,p = 0.48.
One-way analysis of variance (ANOVA) demonstrated that NSAID group did not
differ in terms of baseline MMSE and CDR-SB scores, F= 0.15, df= 293,p = 0.93;

F= 0.75, df= 325,p = 0.52; age, F= 1.48, df= 327,p = 0.22; and education, F= 0.24,
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4[= 327,p = .871. Characteristics ofNSAID exposure level according to these four
levels are illustrated in Table 6.

MMSEScores
Linear mixed models demonstrated that the timing ofNSAID use exposure,
before, after, or both before and after AD diagnosis, was not significantly associated with
overall MMSE scores, LR x2 = .44, df = 4, p = 0.97. Also, the timing ofNSAID
exposure did not significantly impact the rate of cognitive decline, LR x2 = 3.30, df= 6,
p = 0.51. There was no effect ofNSAID use on overall MMSE scores among the
subgroup of persons starting out with mild dementia (global CDR-SBs :SI; n = 283,
LRx2 = 6.2, df= 4,p = 0.18), nor rate of cognitive decline, LR x2 = 8.7, df= 6,p = 0.19.
Inclusion of covariates level of education, age at dementia onset, dementia duration,
gender, and APOE genotype did not alter the relationship between NSAID use and
overall MMSE scores or decline in MMSE over time. Subjects with higher levels of
education demonstrated higher overall MMSE scores than subjects with lower levels of
education. LR x2 = 5.21, 4[= 1,p = 0.02, ~ = 0.2. The final model also showed that
subjects who had longer dementia duration periods had lower overall MMSE scores,
LRx2 = 28.51, df= l,p < 0.001, ~ = -1.09. The final model showed that female subjects
also declined quicker on the MMSE than males, LRx2 = 6.45, df= l,p = 0.01, ~ = -0.88.
Age interactions with NSAID use showed no significant differences in overall MMSE
scores, LRx2 = 2.67, df= l,p = 0.11, nor rates ofMMSE decrease throughout study
visits. LRx2 = 3.01, df= 3,p = 0.39.

Table6
Four-level NSAID Variable Descriptives

Non-NSAID users

Pre-AD NSAID use only

Both pre- and post-AD
NSAJDuse

Post-AD NSAID use only

Sample

characteristics Number
Gender
Male

Female
Age at
dementia

58
85

%

Mean

SD

40.6**
59.1**

Number

%

18
39

31.6**
68.4**

Mean

SD

Number

%

14
18

43.8
56.3

Mean

SD

Number

%

22
73

23.2**
76.8**

Mean

SD

143

84.36

6.46

57

85.37

5.46

32

82.41

7.15

95

84.05

6.54

Education

143

13.27

3.17

57

13.33

3.10

32

13.28

2.58

95

12.98

2.87

Baseline

129

21.90

4.12

53

22.25

4.68

29

21.85

3.65

85

21.71

5.50

6.23

3.45

57

5.45

2.55

32

6.13

1.97

94

5.90

4.07

onset

MMSE
Baseline CDR
**=significant

143
at the .OJ level.

V,
(;.)
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CDR-SB Scores

NSAID use, before or after AD diagnosis, did not significantly affect overall
CDR-SB scores, LRx2 = .50, df= 4,p = 0.96, nor rate of change in CDR-SB over time,
LRx2 = 4.26, df= 6,p = 0.64. There was no effect ofNSAID use on overall MMSE
scores among the subgroup of persons starting out with mild dementia (global CDR-SB's

:S l; n = 283, LRx2 = 5.7, df= 4,p = 0.22, nor rate of cognitive decline, LRx2 = 5.9, df=
6,p = 0.43. Inclusion of the covariates level of education, age at dementia onset,
dementia duration, gender, and APOE genotype did not significantly change the results of
the effects ofNSAIDs. Subjects with longer periods of dementia duration were associated
with higher levels of functional impairment, LRx2 = 64.52, df = l,p < 0.001,

~

= 1.16.

In addition, males had significantly higher overall CDR-SB scores than women, LRx2 =
3.58, df= 1,p = 0.058,

~

= 0.71. Age interactions with timing ofNSAID use showed no

significant differences in overall CDR-SB scores, LRx2 = 1.23, df= 4,p = 0.87, nor rates
ofCDR-SB increase throughout study visits, LRx2 = 3.78, df= 6,p = 0.71.
Cox Regression (mortality). To examine the relationship between the timing of

NSAID use and mortality, I plotted Kaplan-Meier survival curves according to the four
levels ofNSAID use. As can be seen from the plot below (Figure 6), there appears to be
separation of curves between groups I and 3. Median survival time also appeared to be
different between groups 1 and 3 (no NSAID use versus postdementia NSAID use only).
Table 7 displays the median survival times of the four groups.
Despite significant log rank test, timing ofNSAID use was not significantly
associated with survival duration. Hoever, there appeared to be a trend where members
in group I (predementia NSAID use only) exhibited a 13% greater risk for death than
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Table 7
Estimated Median Scores for 4 Level NSAID Variable

Estimated medians
(SD)

1.0

Group 2
(Predementia
NSAID use only)
4.30
(.38)

Group I
(no NSAID use)
5.50
(.29)

Group 3
(Postdementia
NSAID use only)
6.90
(.72)

Group 4
(Pre- and
postdementia
NSAID use)
5.59

(.34)

4 level NSAID use
variable

+
+

no use ever
pre-dementia use only

post-dementia
use only

0.8

both pre and post

dementiaNSAIDuse
no use ever-censored

.;
.2:
>

pre-dementiause onlycensored
post-dementia
use only-

0.6

censored

!:l

bothpre and post
dementiaNSAIDuse-

ifJ.

1::1
<I)
uI-<

censored

0.4

<I)

Ps
0.2

0.0
0.00

2.00

4.00

6,00

8.00

10.00

Number of Visits

Figure 6. Kaplan Meier plot for 4 level NSAID variable.
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group O (no NSAID use group), HR= 1.13, df= 3,p = 0.07, CI= .93, 1.19. When
including the covariates education, age at baseline, dementia duration, gender and APOE
genotype, only onset age for dementia significantly predicted survival outcomes, with
older individuals having a 9.3% greater risk of death over younger individuals, HR=
1.093, df= 1,p < 0.001, CI= 1.067, 1.119.

Research Question 3: Does the duration ofNSAID use affect
the rate of cognitive and functional decline and
survival duration in individuals with AD?

As mentioned above, approximately 56% of the sample had at least some degree
ofNSAID use. The average duration ofNSAID use at any point before, during, or after
dementia onset for those with at least one month of use, either pre- or postdcmcntia, or
both, was 6.14 years (SD= 6.83). Predementia use averaged 4.68 (SD= 6.34) years, and
postdementia use averaged 1.46 (1.72) months of use. The distribution ofNSAID use was
positively skewed. Frequency distributions of pre- and postdementia use, as well as total
NSAID duration of use are presented below in Figures 7, 8, and 9.
In further exploratory analyses, I expressed duration ofNSAID use in tertiles and
examined baseline differences in subjects. The first tertile used anywhere from 1 to 30.8
months ofNSAID use, the second tertile had anywhere from 30.96 to 70.55 months of
NSAID use, and the highest tertile had anywhere from 74 to 569.10 months ofNSAID
use. One-way ANOV A revealed no significant differences between these three groups in
terms oflevel of education, length of dementia duration, or baseline MMSE or CDR-SB
scores, F= 0.185, df= 2,p = 0.86, F= 0.672, df= 2,p = 0.51, respectively. However,
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Figure 7. Total NSAID use.

subjects in the first tertile ofNSAID use were significantly older than subjects in the last
tertile ofNSAID use, F = 1.63, df= 29,p

=

0.03. There was a higher proportion of

females than males in each group (Group 1: x2 = 4.74, df = l,p

=

0.03; Group 2:

x2 = 13.79, df = l,p < 0.001; Group 3: x2 = 15.25, df= l,p < 0.001). Decriptive
statistics are provided for each group in Table 8.
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Figure 8. Predementia NSAID use only.
MMSEScores
Duration ofNSAID use did not significantly affect overall MMSE scores, LRx2 =
1.23, df= 1,p = 0.26, nor did duration ofNSAID use significantly affect rate of cognitive
decline, LRx2 = 0.725, df= 2,p

= 0.70.

There was no effect ofNSAID use on overall

MMSE scores among the subgroup of persons starting out with mild dementia (global
CDR-SBs :-,:l; n = 283, LRx2

= 1.2, df= I,p = 0.27, nor rate of cognitive decline, LRx2

= .89, df = 2,p = 0.35. Addition of the covariates level of education, age at dementia
onset, dementia duration, gender, and APOE genotype, did not alter the relationship
between NSAID use and MMSE scores. Higher levels of education were associated with
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Figure 9. Postdementia NSAID use only.
greater overall MMSE scores, LRx2 = 5.012, ~ = 0.22, df = l,p = 0.02. Subjects with
longer periods of dementia duration at baseline were associated with lower overall
MMSE scores, LRx2 = 28.057, ~ = -1.07, df= 1, p < 0.001. Female subjects were also
shown to decline in MMSE scores quicker than males, LRx2 = 7.359, ~ = 0.78, df = 2,
p = .025. To zero in on any NSAID duration effects after dementia onset, I also

conducted the same analyses but limited NSAID use duration to NSAID use only
following AD onset. However, results from this model were similar to the results in the
model above with NSAID use having no effect on overall MMSE scores, LRx2 = 1.23,
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Table 8

Descriptives ofNSAID Tertile Groups
Group I {ltrstterttlej

Group3 (tlurOtertileJ

Group 2 (secona terttlej

Sample
Characteristics

Number

%

Mean

SD

Number

%

Mean

SD

Number

%

Mean

SD

en er
Male

22

36.0*

16

26.2*'

16

25.4**

Female

39

64.0*

45

74.8**

47

74.6**

Age at dementia

61

85.79**

6.04

61

83.97

6.58

63

82.58**

6.40

Education

61

13.68

2.45

61

12.79

3.05

63

12.98

2.72

AD duration

61

1.50

1.21

62

1.73

1.23

62

BaselineMMSE

54

22.25

3.83

55

21.82

4.59

59

21.76

6. 10

Baseline CDR

61

5.56

2.06

60

5,61

3.03

63

6.18

4.40

onset

1.98

I.SO

* significant at the .05 level.

** significant at the .001 level.

df= l,p = 0.27, nor the rate of cognitive decline, LRx2 = 4.37, df= 2,p = 0.13. Age
interactions with duration ofNSAID use also showed no significant differences in overall
MMSE scores, LRx2 = 0.87, df = I,p = 0.65, nor rates ofMMSE decline over the study
visits, LRx2 = 2.53, df= 2,p = 0.28.

CDR-SB Scores

Duration ofNSAID use did not significantly impact overall CDR-SB scores,
LRx2 = 2.17, df= I,p = 0.15, nor rate of change in CDR-SB scores, LRx2 = 3.14, df= 2,

p = 0.21). There was no effect ofNSAID use on overall MMSE scores among the
subgroup of persons starting out with mild dementia, LRx2 = .79, df= I,p = 0.36, nor
rate of cognitive decline, LRx2 = 2.92, df= 2,p = 0.23. The addition of the covariates
level of education, age at dementia onset, dementia duration, gender, and APOE genotype
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did not alter the relationship between duration ofNSAID use and CDR-SB. Only
dementia duration had any impact on overall CDR-SB scores, showing that longer
periods of dementia duration were associated with increased CDR-SB scores, LRx2 =
61.75,

~

= 1.12, df= l,p < 0.001. Age interactions with duration ofNSAID use also

showed no significant differences in overall CDR-SB scores, LRx2 = 2.63, df= l,p =
0.11, nor rates of CDR-SB change over the study visits, LRx2 = 1.90, df= 2,p = 0.17.

Cox Regression (Mortality)

Due to the limitations of the data, no Kaplan-Mier plots were able to be produced.
However, Cox Regression models were conducted demonstrating that the duration of
NSAID use was not significantly associated with risk for mortality, HR= 1.04, df = 1,
P = 0.41, CI(95) = .996, 1.01. Inclusion of the covariates education, age at baseline,

gender, and APOE genotype did not alter this result. Earlier onset age of dementia
significantly increased one's chances of mortality, HR= 1.09, df= 1,p < 0.001, CI=
1.07, 1.12, as did male sex, HR= 1.427, df= 1,p = .01, CI= 1.08, 1.90.

Power Analysis

In view of the null results found in the previous three research questions, I
conducted a power analyses to determine whether the current analyses with the linear
mixed models were underpowered. According to Fitzmaurice and colleagues (2004),
there are several items under consideration when calculating power with longitudinal
data: (a) the mean amount of study follow-up visits, (b) the standard deviation of number
of follow-up visits, (c) the estimated effect size, and (d) and the number of participants in
the study. For the power analyses in this study, I limited the participants to those who
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had only completed at least one follow-up visit. Of the 328 participants, only 216 had at
least one follow-up visit, therefore restricting my number value in the cmTent analyses to
216 instead of 328 participants. My estimated effect size for the MMSE was 0.27, and
for the CDR-SB was 0.54. I selected these values based from findings reported by
Mielke et al. (2007) that suggested such effect sizes between antihypertension
medications and cognitive and functional decline in a sample of AD patients. In Table 9
are listed the calculated power estimates for effect sizes that range from small (0.2),
medium (0.5) and large (0.8), according to Cohen (1988).
As can be seen from the table below, with a chosen effect size of 0.27 for the
MMSE and 0.54 for the CDR-SB, the power analysis suggests that this study had
adequate power to detect medium and large effect sizes, but not a small effect. Although
such results were not discovered in the analyses from this study, such nonsignificant
findings are not considered the result of being underpowered.

Table 9
Power Analyses
Estimated power
MMSE

CDR

Small effect size (.2)

46%

48%

Medium effect size (.5)

84%

99.5%

Large effect size (.8)

99.9%

99.9%

63

Subgroup Analysis: 2+ Years of
Preonset SAID Use
In analyses examining a subgroup with greatest potential to show an effect for
NS AID use (based on the literature), I examined individuals who had at least two years of
predementia NSAID use and continued use after dementia onset versus persons who
never used NSAIDs. There were 66 individuals who fell into the NSAID use (2+ years of
predementia use, and at least some postonset use) group and 262 remaining participants
not meeting these criteria. Even with categorizing the data in this manner, results were
largely the same as other results attained in this project. Linear mixed models
demonstrated that NSAID users (defined as 2+ years of predementia NSAID use) did not
differ from nonusers in terms of their overall MMSE scores, LRx2 = 2.14, df= 2,p =
0.35, nor rate of cognitive decline, LRx2 = 1.04, df = 4, p = 0.97. There were also no
overall differences in overall CDR scores between these two groups, LRx2 = 3.19, df= 2,

p = .20, or CDR change scores through time, LRx2 = 3.70, df= 4,p = 0.45. Lastly, there
were no differences between these two groups in terms of their risk of mortality, HR=
1.11, df= I,p = 0.13, CI(95) = .09, .17.

Research Question 4: Is there any evidence of APOE e4
interaction with NSAID use on the rate of cognitive and
functional decline and survival duration
among individuals with AD?

To describe my sample in terms of APOE E4 presence, I divided those who
possessed at least one APOE E4 allele into one group and those that did not into another.
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Participants numbering 181 possessed at least one APOE E4 allele (55.1%), whereas 147
did not. Table 10 displays the frequency ofNSAID use by APOE E4 group.
In the APOE E4 group 76 participants had no NSAID use and 103 had at least one
month ofNSAID use. Of the 103 participants in the APOE E4 group roughly one third of
the group fell into each of the 1st, 2nd , and 3rd tertile use groups. In the no APOE E4 group
65 participants had no NSAID use and 82 had at least one month of use. Similarly, as in
the APOE e4 group, the no APOE E4 group had roughly one third of the group in each of
the 1'1, 2nd, and 3rd tertile use groups. In participants with at least one month ofNSAID
use, there were no significant differences between the two APOE groups in terms of
average total NSAID use, T= 0.79, df= 180,p = 0.43.

Table 10

NSAID Use by APOE e4 Group

NSAID Use (n = 185)
No NSAID use (n = 141)

APOEe4
103 (56%)
76 (54%)

NoAPOEe4
82 (44%)
65 (46%)

Length of use by APOE genotype (Mean/SD)
1st tertile
(1-30.8 months ofNSAID use)

32(31.1%)

29 (35.4%)

2nd tertile
(30.96-70.55 months ofNSAID use)

38 (36.9%)

23 (28.0%)

3rd tertile
(74.0-569.1 months ofNSAID use)

33 (32.0%)

30 (36.6%)

73.1 (64.82)

83.4 (96.32)

Total months ofNSAID use
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In the results presented above, presence of APOE s4 did not significantly affect
overall MMSE and CDR-SB scores nor their progression through time. To answer
research question 4 (whether effects ofNSAID use were modified by genotype at
APOE), I tested an interaction between presence of APOE s4 and NSAID use as defined
in the previous research questions in linear mixed effects models. In reference to
ever/never NSAID use, there was no significant interaction between NSAID use and
presence of APOE s4 in predicting overall MMSE or CDR-SB scores, LRx2 = 3.01, df=
2,p = 0.18, LRx2 = 4.06, elf= 2,p = 0.13, nor the rate of change in MMSE or CDR-SB
scores, LRx2 = 4.89, df= 3,p = 0.30, LRx2 = 6.05, df= 3,p = 0.11. In reference to the
timing ofNSAID use, before or after AD onset, there was no interaction between NSAID
use and APOE and their effect on overall MMSE or CDR-SB scores, LRx2 = 6.45, elf= 4,
p = 0.17, LRx2 = 5.87, df= 4,p = 0.21, nor rate of change in MMSE and CDR-SB
scores, LRx2 = 7.55, df= 6,p = 0.27, LRx2 = 5.71, df= 6,p = 0.46. Lastly, the
interaction between duration ofNSAID use and APOE also did not significantly affect
overall MMSE or CDR-SB scores, LRx2 = 2.73, df= l,p = 0.l 1, LRx2 = 2.32, df= 1,
p = 0.13, nor rate of change in MMSE and CDR-SB scores, LRx2 = 1.45, df= 2,p =
0.48, LRx2 = 2.84, df= 2,p = 0.24.
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CHAPTERV
DISCUSSION

In this project I proposed to research the effects ofNSAIDs on the progression of
cognitive and functional impairment and survival duration in AD. I did this by
examining NSAID use in a variety of different ways, specifically, use of any type of
NSAID, timing ofNSAID use in relation to the onset of dementia, and the duration of
NSAIDuse.
The results from this project suggested that NSAID use, defined by any of the
methods described above, does not affect the rate of cognitive or functional decline in
persons after the onset of AD. These results support the null hypothesis (no effect).
Power analyses that were conducted suggested that there was sufficient power to detect a
moderate effect size (approximately .5), which supports the notion that NSAIDs may not
have an effect on cognitive or functional decline after the onset of AD. While the study
was sufficiently powered to detect moderate or large effect sizes, the power to detect
small effects was only 48%.
A discussion of the results found in this study would not be complete without
discussing potential reasons for the lack of impact NSAIDs have on AD progression once
AD has been diagnosed, despite relatively robust data that suggests NSAIDs can delay
the onset of AD (see Literature Review). As reviewed previously, the prophylactic
nature ofNSAID use on AD results from the antiinflammatory effect NSAIDs have on
the central nervous system. Because neuroinflammation plays a significant role in the
development ofNFTs and beta-amyloid plaques (Frackowiak et al., 1992; Mackenzie et
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al., 1995; Perlmutter et al. 1990), medications that decrease inflammation are likely to
affect the degree ofNFTs and beta-amyloid plaques that build up over time, thus
postponing the accumulation of the biological agents responsible for AD. This is the
theoretical basis upon which hypothesis of NS AID use and their purported effect on AD
progression is based. However, most of the evidence that NSAIDs postpone or delay the
onset of AD has risen primarily from epidemiological evidence, not necessarily from
RCTs. RCTs that have looked at the onset of AD and its relationship to NSAID
medication have not provided such auspicious results. For example, in 2007 the National
Institute on Aging (NIA) sponsored a large placebo-controlled RCT of naproxen and
celecoxib (both NSAIDs) and their purported effect on the risk of AD. Although the
study terminated prematurely due to discovered cardiovascular risks in taking naproxen
and celecoxib, analyses of the data gathered prior to termination found no benefit of
either NSAID use, but also suggested that naproxen and celecoxib use may lead to an
increased risk of developing AD (Lyketsos et al., 2007). Lyketsos and colleagues
discussed their findings in conjunction with other research that protective effects stem
from epidemiologic studies, but not from clinical trials. Results from epidemiological
studies may suggest the presence of confounding variables that complicate the
relationship between NSAID use and AD risk (Lyketsos et al., 2007).
In addition, the Adult Changes in Thought (ACT) study conducted by Arvanitakis
and colleagues (2008), also found an increased risk of AD with associated NSAID use.
One difference in this study when compared to other studies in the field was that
Arvanitakis and colleagues were able to not only note NSAID use, but the dose of
NSAIDs consumed. They divided their sample ofNSAID users into three categories: (a)
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heavy, (b) moderate, or (c) light NSAID users. In the light to moderate categories, they
found no relationship between NSAID users and nonusers in hazard ratios for developing
AD. However, they found an increased risk of developing AD with heavy NSAID users,
even after adjusting for potential confounding variables, such as age, sex, and education.
Their results suggested that dosage is an important variable, and that representing NSAID
use as a simple dichotomy of use/no use may lead to spurious or misleading results
(Arvanitakis et al., 2008). Other studies have also found that dosage is an important
variable to consider when examining the relationship between NSAID use and AD onset
and progression (Broe et al., 2000)
The purported link between NSAID use and the development of AD can be
questioned, and may only exist under certain conditions, such as for a certain dosage of
NSAIDs or in observational studies where potential confounding variables are not fully
considered. One of these factors may be age. Well-known studies such as the Rotterdam
study have found an negative association between NSAID use and AD onset in younger
samples, but no association in older samples (In't Veld et al., 1998). Perhaps studies that
do not report a beneficial effect, such as the ACT study (Arvanitakis et al., 2008), reflects
differences in age of use and age of the population being studied. The ACT study and
many others in the field have studied NSAID use in late life, in much older participants
than that of Rotterdam. It is possible that age may be a moderating factor of the effects
ofNSAID use on AD risk. The literature would suggest a lower risk of AD with
NSAIDs in younger but not older individuals (Bennett & Whitmer, 2009).
Another reason for the negative results of this study may have to do with the
nature ofNSAIDs and how they operate in decreasing inflammation in the brain.
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Although NSAIDs may decrease inflammation and the accumulation of
neuropathological markers of AD (i.e., NFTs and beta-amyloid plaques), it may be that
such prophylactic effects have run their course after NFTs and beta-amyloid plaques have
already set in, thus resulting in limited to no effects of NSAIDs after the diagnosis of AD
is made. Although there is evidence that NSAIDs can decrease neuroinflammation, thus
postponing or decreasing the accumulation ofNFTs and amyloid plaques, there is no
evidence that suggests NSAIDs can reverse the damage that has already occurred or
reverse the amount ofNFTs and amyloid plaques that have already aggregated in the
brain of persons with AD (Cole & Frautschy, 2010). AD has a long preclinical period.
In fact, recent research has suggested that subtle cognitive changes, primarily age-related
memory decline, can occur up to decades before the actual clinical presentation of AD
symptoms (Caselli et al., 2009). It is possible that the inflammatory processes thought to
contribute to AD may also be occurring well before the actual onset of symptoms. Thus,
NSAIDs may exert effects in preclinical stages, but may have no effects after the onset of
AD. After disease onset, compounds that reverse the damage exerted by the disease
(unlikely), prevent further damage, or promote neurogenesis would likely be of benefit;
however, these activities are not likely to be part of the medicinal actions ofNSAID
medications (Cole & Frautschy, 2010).
As an aside, in posthoc analyses, I did attempt to examine possible effects of
NSAIDs on those with mild AD, by restricting analyses of the first three research
questions to those with a global CDR of<= 1, where plaque and NFT burden would
likely be lower than those in the advanced stages of the disease. However, the results
were largely the same as other results obtained in this study, that NSAIDs did not
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significantly affect cognitive or functional outcomes. Additionally, reseai·ch into the
effects ofNSAIDs in Mild Cognitive Impairment (MCI), a prodrome to AD, has also
yielded negative results, indicating that NSAIDs are not effective in either slowing the
cognitive decline of MCI nor the rate of conversion of MCI to AD (Aisen et al., 2008;
Thal et al., 2005). This would suggest that at the point of symptom expression, NSAIDs
are not an effective treatment to reduce the cognitive decline nor emergence of AD.
While the results of the current project suggest that NSAIDs are not effective in
treating AD, it does not necessarily follow that neuroinflammation does not influence the
progression of symptoms in AD. Although there is a link between NS AID use and a
reduction of inflammation, there is no direct link between peripheral NSAID use and
degree ofneuroinflammation within the brain. To directly measure the amount of brain
inflammation, measurements of inflammatory markers such as tumor necrosis factoralpha (TNF-a), C-reactive protein (CRP), and other cytokines (such as interleukins 2, 6)
would need to be assayed, preferably from cerebrospinal fluid. Such biomarkers are
direct measures of inflammation, and have been shown by several studies to be associated
not only with the risk for AD, but also with the progression of the cognitive symptoms of
AD (Bermejo, Martin-Aragon, & Benedi, 2008; Holmes et al., 2009; Tan et al., 2008).
The results of the survival analyses indicated no significant association between
NSAID use and survival duration in AD. A few previous studies exainining mortality
and NSAID use among individuals with AD have actually demonstrated an increase in
mortality rates, primarily because of cardiovascular risk factors associated with NSAID
use (Psaty & Kronmal, 2008). Such results have led to several NSAID medications to be
removed from the market and discontinuation of FDA (Federal Drug Administration)
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approval (Psaty & Kronmal, 2008). Although the results of this study did not find
significant results, there was a trend that individuals taking NSAIDs prior to AD onset
had a 13% increased hazard of death when compared to those not taking NSAIDs, which
would be consistent with findings from previous studies. However, this result did not
reach statistical significance (p = .07), and it may be that a subgroup of persons, such as
those with vascular comorbidity, may exhibit greater risk for mortality than others. An
understanding of the relationship between NS AID use and mortality warrants further
research in this area.

Strengths and Limitations of the Current Study

There are several strengths and limitations of the study that warrant discussion.
Based on the literature, two main issues regarding the pattern ofNSAID use were
identified: (a) Does the timing ofNSAID use matter in relation to AD progression? and
(b) Does the duration ofNSAID use matter in relation to AD progression? One of the
strengths of this study was that it addressed both of these questions. The results from this
study also suggest that despite using NSAIDs before or after AD diagnosis there is no
impact ofNSAID use on the progression of AD.
Addressing the issue of the duration ofNSAID use has two benefits. First, as
discussed above, it addresses the question posed by Breitner (1996), that perhaps 2 years
of continuous use ofNSAIDs is necessary to impact the risk of AD. In addition, it also
fills a gap in the literature in reference to the RCTs reviewed in this project. Three of the
four RCTs on NSAID use and cognitive decline in AD yielded negative results, however,
the follow-up times for these RCT's were all! year or less, a period of time that has been
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argued insufficient to incur beneficial effects. Several researchers have called on studies
oflonger duration (exceeding 1 year) to examine the question regarding duration of
NS AID use and its impact on cognitive decline in AD. Although the current study is not
an RCT, and therefore inferences regarding this study cannot be directly compared with
results from such studies, this observational study did follow the cognitive trajectory of
individuals taking NSAIDs for more than one year, a previous limitation to the studies
reviewed earlier.
The results discussed in this project stem from a population-based study
conducted in Cache County, Utah. There are obvious benefits from conducting such a
study in a population such as avoiding the biases associated with clinic-based samples,
allowing one to generalize the results to larger populations. Although this study enjoys
this strength, it must also be remembered that the population of older persons studied by
the CCSMHA is primarily Caucasian (99%), with the majority consisting of followers of
The Church of Jesus Christ of Latter-day Saint religion. Therefore, despite the overall
generalizability of population-based studies, the results of this study are not easily
generalizable to populations with greater ethnic diversity. Other strengths of the current
study include a careful and thorough diagnosis of AD. As reported in the Methods
section, diagnoses of AD were only given after a thorough review of data by experienced
clinicians in geropsychiatry, neurology, and neuropsychology. In addition, this study
included multiple periods of observation post-AD onset that covered prolonged periods
of time to allow me to examine duration ofNSAID use after the onset of AD.
In addition, one limitation shared by all studies in this area of research is the
difficultly in attempting to gather information regarding medication history. Factors such
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as recall bias and overall forgetfulness may introduce errors in the report of medication
use, especially in a population diagnosed with memory impairment (Fendrich &
Rosenbaum, 2003; Romeo, 1997). The methods used in this study (conducting a
medicine chest inventory) have been used in a number of other studies of the effects of
medication (Fendrich & Rosenbaum, 2003; Romeo, 1997). However, despite this, the
inventory ofNSAID use, particularly prior to the onset of AD, was examined at 3-year
intervals so recall bias may be a more significant issue than the more frequent inventories
completed after the onset of dementia.

Future Directions

To further our understanding of the relationship between AD progression and
inflammation as well as NSAID use, a futt.u-earea of research is to examine the
relationship between inflammatory markers and their relationship to AD progression.
Although much research has been done in the past linking neuroinflanunation and risk for
AD, little has been done in linking neuroinflanunation with the progression of AD
symptoms after dementia onset, although there is at least some research that suggests
inflammatory biomarkers are associated with decreases in total brain volume in the
elderly (Jefferson et al., 2001). Research has shown that some inflammatory markers are
predictive of cognitive decline in elderly individuals whereas other studies show no
association (Diket al., 2005; Schram et al., 2007). Research examining whether there are
differences between individuals with MCI and AD are mixed. Some research studies
have found significant differences between MCI and AD in terms of inflammatory
markers, suggesting that greater levels of neuroinflammation is associated with decreases
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in cognitive functioning (Guerriero et al., 2007), whereas other studies have failed to find
this association (Bermejo et al., 2008).
Research examining the relationship between inflammatory markers and cognitive
decline in AD has also been mixed. For example, Holmes and colleagues (2009)
examined 300 individuals with mild to moderate AD and their relationship between
inflammatory markers and cognitive decline. In their study, they found that acute
inflammatory events (e.g., such as blow to the head, short-lived infection [less than 2
months]) were associated with increases in levels of tumor necrosis factor-alpha (TNFalpha), which were associated with increases in rate of cognitive decline over a 6-month
period. Participants who had low levels ofTNF-alpha (low levels of inflammatory
markers) showed no cognitive decline over the same period (Holmes et al., 2009).
However, other studies have not provided such promising results. Lanzrein and
colleagues (1998) examined assays from the cerebrospinal fluid from 8 individuals with
AD and compared them with samples with 9 controls. Sampling actual cerebrospinal
fluid levels ofinflammat01y markers allowed them to examine inflammation of the brain.
They examined a host of different proteins involved in the inflammatory process,
including a variety of different cytokines, TNF-alpha, and interleukins (IL-6, IL-I beta).
In their study, they found no differences in inflammatory markers between the two
samples. Although the latter study suffers from small sample sizes, it does raise certain
questions about the source of inflammatory markers (cerebrospinal fluid vs. blood), the
extensive number of factors that are involved in the inflammatory process, and whether
inflammation plays a more prominent role in early versus later stage disease. Are there
some factors that are more important than others? Do some factors, such as TNF-alpha in
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the Holmes et al. (2009) study have an impact on AD progression whereas others do not?
Future research in the area of inflammatory markers and AD progression should examine
these and other questions. In addition, there may be an interactive effect between the
presence of APOE

E4

alleles, neuroinflammatory markers such as TNF-alpha and other

cytokines, and cognitive decline in AD (Blasko et al., 2007).
In summary, the results of this study found no effect ofNSAID use on the
progression of AD. For future work in this area, it is recommended to first establish a
research base examining the link between neuroinflammation and AD progression before
examining the effects of compounds that reduce inflammation. If research demonstrates a
relationship between these two variables, additional work can be done in the area of
NSAID use and progression of AD, in attempting to research not only the relationship
between these two variables, but their potential interactive effects with dose of use, age,
and study methodology.
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3-NPBrit-CJ•

S·S Bric.Cl'
6-S Brk-Pl*
61-S Brk•Other•
7-Cog-Untest
8-0thcr-NA"
9-S Rf

4-NPBrk•Pt•

JO-No Time•

l• Comp-NoPl
20. Comp-Other•
21-CompPl:9/l
22-CompPl>JP!
l•Comp-PJ•

11-JMS

1-StndPro

COMMENTS: __________

_

2-D~vPro•
21-0lher lkv Pro
22-SubDevPro
3-NA
4-lMS for MMSE

rorMMSE
TIME:w:w
MINI-MENTALSTATEEXAMINATION

Now I would like to ask you some questions to check your memory and concentration. Some of them may be easy
and some may be hard,

L

2.

What Is the year?

What Is the season of the year?

3. What Is the date?

4.

What is the day of the week?

5. What is the month?

ERROR...............
......................0
CORRECT ........,............., .................................. 1
INCORRECT: PHYS lMP.
................6
NOT ASSESSED ............................................... 9

IMP
l-$ight

2-hearing
3-hands
4-olhei

ERROR ............................................................... O
CORRECT .......................................................... !
INCORRECT: PHYS lMP ..................................6
NOT ASSESSED ................................................ 9

!MP

ERROR ............................................................... O
CORRECT..........................................
... I
INCORRECT:PHYS IMP...
. ....................6
NOT ASSESSED......
. ........9

!MP

ERROR............................................................... O
CORRECT..........................................................!
INCORRECT: PHYS lMP ..................................6
NOT ASSESSED ................................................ 9
ERROR............................................................... O
CORRECT .......................................................... !
INCORRECT: PHYS lMP ..................................6
NOT ASSESSED ................................................ 9

LJ
LJ
!MP

LJ
!MP

LJ

6. Can you tell me where we are right now? (For
instance, what state are we in?)

ERROR............................................................... O
CORRECT .......................................................... !
INCORRECT: PHYS lMP ..................................6
NOT ASSESSED........
.......................9

LJ

7.

ERROR ............................................................... O
CORRECT .......................................................... !
INCORRECT: PHYS lMP ..................................6
NOT ASSESSED ................................................ 9

LJ

What county are we in?

8. What city/town are we in?

9.

What floor of the building are we on'!

ERROR ............................................................... O
CORRECT .......................................................... !
INCORRECT: PHYS lMP ..................................6
NOT ASSESSED ................................................ 9
ERROR ............................................................... O
CORRECT .......................................................... !
INCORRECT: PHYS lMP ..................................6
NOT ASSESSED ................................................ 9

!MP

IMP

!MP

LJ
IMP

LJ
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What is this address? (If institutionalized,
what ls the name of the Institution?)

JO.

l I.

ERROR ............................................................... O
CORRECT .......................................................... I
INCORRECT:
PHYS IMP..................................6
NOT ASSESSED................................................ 9

IMP

LJ

lam going to name three objects. After I have said them, I want you to repeat them. Remember what
they are because I am going to ask you to name them again in a few minutes.

Please repeat the names for me:
SCORE FIRST TRY. REPEAT OBJECTS FOR UP TO THREE TRIALS ONLY.
Trial3

LJ

APPLE

LJ

f~;~:~~iiiiiso:·:.
: •• [J

TABLE---------------PENNY- --------------12.

IMP

SCORE................................
INCORRECT: PHYS IMP ............................... 6
9
~gJ

LJ

ERRORS DUE TO PHYSICAL IMP

Now I am going to give you a word and ask you to spell It forwards and backwards. The word is
WORLD. First, can you spell It forwards? Now spell it backwards, REPEATIF NECESSARY. HELP
SUBJECTSPELLWORDFORWARD,IFNECESSARY.SCORENUMBEROF LETTERSGIVENIN
CORRECTORDER,

w

-L-

-D-

L

R

IN

-0-

LJ

SCORE ...............................
POSITION SCORE ........................
INCORRECT: PHYS lMP ............................... 6
NOT ASSESSED ..........
..................... 9

LJ

IMP

lJ

What were the three objects I asked you to remember?
13.

14.

15.

16.

APPLE

TABLE

PENNY

POINTTOA WATCH, Whatisthiscalled?

ERROR OR OMISSION ..................................
CORRECT.......................................................
INCORRECT: PHYS IMP ..............................
NOT ASSESSED ............................................

0

[MP

1
6
9

LJ

ERROR OR OMlSSION ..................................
CORRECT........................................................
INCORRECT: PHYS IMP ...............................
NOT ASSESSED .............................................

0
I
6

lMP

ERROR OR OMISSION .................................. 0
CORRECT........................................................ I
INCORRECT;PHYS IMP............................... 6
NOT ASSESSED ............................................. 9
ERROR.............................................................
CORRECT........................................................
INCORRECT: PHYS IMP ...............................
NOT ASSESSED .............................................

LJ

9

O
I
6
9

IMP

LJ
IMP

LJ
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17. SHOWA PENClL.What is this called?

18.

19.

20.

I would like you to repeat a phrase after me:
(THE PHRASE IS) 'No ifs ands or buts.'
ALLOW ONLY ONE TRIAL. PHRASE MAY BE
REPEATED IF REQUESTED BY SUBJECT
BEFORE A FIRST ATTEMPT.

Read the words on this page 1 than do what it
says. THE PAPER READS: "CLOSE YOUR
BYES." SCORE CORRECTIF SUBJECT
CLOSES EYES.

Folds

In lap

22.

ERROR OR OMISSION.

............ 0

CORRECT......................

. .. I

INCORRECT: PHYS IMP ................... ........... 6

NOT ASSESSED ...........................

IMP

LJ
IMP

LJ

.. ......... 9

ERROR OR OMISSION .................................. 0
CORRECT....................................................... 1
INCORRECT: PHYS IMP....
.. ......... 6
NOT ASSESSED ............................................ 9

IMP

LJ

I am going to give you a piece of paper. When I
do, take the paper in your right hand, fold the
paper in half with both hands, and put the paper
down on your lap.
READ FULL STATEMENT, THEN HAND
PAPER TO SUBJECT. DO NOT REPEAT
INSTRUCTrONS OR COACH.
Righthand

21.

ERROR............................................................ 0
CORRECT ..................................................... I
INCORRECT: PHYS IMP..........
...... 6
NOT ASSESSED..........
.. .................... 9

Write any complete sentence on that piece of

ERROR................................. .. ..................... 0
CORRECT........................
.. ............. 1
INCORRECT: PHYS IMP ............................. 6
NOT ASSESSED .......
.. ..................... 9

LJ

ERROR............................................................

IMP

0

CORRECT....................
........... I
INCORRECT: PHYS IMP ............................... 6
NOT ASSESSED ............................................. 9

LJ

ERROR............................................................ 0
CORRECT.......................
.. ..................... 1
INCORRECT: PHYS IMP
..................... 6
NOT ASSESSED ....
.. .......................... 9

IMP

paperfor me.

ERROR............................................................. O
CORRECT........................................................ I
INCORRECT: PHYS IMP ............................... 6
NOT ASSESSED.............................................9

Here Is a drawing, Please copy the drawing on

ERROR ............................................................. O
CORRECT ....................................................... 1
INCORRECT: PHYS IMP ............................... 6
NOT ASSESSED
................... 9

thesamepaper. SCORECORRECT
IFTHE
ORAWING INCLUDES TWO FIVE-SIDED
FIGURES AND IF ALL ANGLES IN THE FIVE•
SIDED FIGURE ARE PRESERVED.

IMP

Total Score
Pos Score

LLJ1 W
W 1W

LJ
IMP

LJ
IMP

LJ
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AppendixB:
CDR-SB
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YES (ENTIRE SECTION) ...................................
INCOMPLETE OR BREAK-OFF ..........................
NO (NO DATA/RF) ............................................

SECTION
COMPLETED

..
.
.

SECTION AD: Consensus CDR Staging
Judgment
and Problem
Solving

Community
Affairs

Fully oriented

Solves
everyday
problems
well:
judgment
good in
relation to
past
performance

Independent
func- tion at
usual level in
job, shopping,
business and
financial affairs,
volunteer and
social groups

Life at home,
hobbies
intellectual
interests well
maintained

Fully capable of
self care

Consistent
slight
forgetfulness;
partial
recollection of
events;
"benign"
forgetfulness

Fully oriented
except for
slight difficulty
with time
relationships

Slight
impairment in
solving
problems,
similarities,
differences

Slight
impairment in
these activities

Life at home,
hobbies,
intellectual
interests
slightly
impaired

Fully capable of
self care

Mild
(1)

Moderate
memory loss;
more marked
for recant
events; defect
interferes with
everyday
activities

Moderate
difficulty with
time
relationships;
oriented for
place at
examination;
may have
geographic
disorientation
elsewhere

Moderate
difficulty in
handling
problems,
similarities,
differences;
social
judgment
usually
maintained

Unable to
function
independently
at these
activities though
may still be
engaged in
some; appears
normal to
casual
inspection

Mild but
definite
impairment
of function at
home; more
difficult
chores
abandoned;
more
complicated
hobbies and
interests
abandoned

Needs
prompting

Moderate
(2)

Severe
memory loss;
only highly
learned
material
retained; new
material
rapidly lost

Severe
difficulty with
time
relationships;
usually
disoriented in
time, often to
place

Severely
impaired in
handling
problems,
similarities,
differences;
social
judgment
usually
impaired

No pretense of
independent
function outside
home. Appears
well enough to
be taken to
functions
outside family
home

Only simple
chores
preserved,
very
restricted
interests,
poorly
sustained

Requires
assistance in
dressing,
hygiene,
keeping of
personal effects

Severe
(3)

Severe
memory loss;

Oriented to
person only

Unable to
make
judgments or
solve
problems

No pretense of
independent
func- tion
outside home.
Appears too ill
to be taken to
functions
outside family
home

No

Requires much
help with
personal care;
frequent
incontinence

Memory

Orientation

None
(0)

No memory
loss or slight,
inconstant
forgetfulness

Questionable (0.5)

onlyfragments remain

Sub-item

I

I

1

II

II 2

LJ

3

II

II 4

Home and
Hobbies

Personal Care

significant
function in
home

II

I

5

II

I

6
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II II

II II

Scores
'=7"==,='
'====='
'===='
b==='
Although rules for assigning CDR stages beyond CDR 3 have not been established, the
following have been proposed to distinguish additional levels of Impairment in advanced
dementia·
Profound
(4)

Terminal
(5)
Sensory-Mtr

confound(91)
Current Staging of
Dementia:
(Computerwill score If
desired)

Speech usually unintelligible or irrelevant; unable to follow simple instructions or
comprehend commands; Occasionally recognizes spouse or caregiver. Uses fingers
more than utensils, requires much assistance. Frequently incontinent despite
assistance or training. Able to walk a few steps with help; usually chair-bound; rarely
out of home or residence; purposeless movements often present.
No response or comprehension. No recognition. Needs to be fed, may have NG
tube and/or swallowing difficulties. Total incontinence. Bedridden, unable to sit or
stand, contractures.
Functional impairment could not be determined due to sensory/ motor impairment

=>No Dementia
0
0.5 =>Uncertain or
deferred diagnosis
=>Mild Dementia
1
=>Moderate dementia
2

3
4
5

=> Severe Dementia

=> Profound dementia
91

=>Terminal Dementia
=> Sensory- Mtr
Confound
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Trevor Buckley
Curriculum Vitae

1078 N. 400 W.
Logan, Utah 84321
(801) 792-7751
t.buckley@aggiemail.usu.edu

EDUCATION
Utah State University, Logan, UT

•
•
•

Ph.D. Candidate, Combined Clinical, Counseling, and School Psychology
Doctoral Dissertation: Does NSAID Use Affect Dementia Progression and
Survival Rates? The Cache County Study.
Chairperson: JoAnn Tschanz, Ph.D.
Dean's list all semesters

Utah State University, Logan, UT
M.S. in Combined Clinical, Counseling, and School Psychology, 2008
• Masters thesis: Measuring unawareness of cognitive decline in a population of
elderly individuals: The Cache County Study.
• Chairperson: JoAnn Tschanz, Ph.D.
• Dean's list all semesters
University of Utah, Salt Lake City, UT

•
•
•

B.S. Major: Psychology, Minor: Spanish
Dean's list
Graduated cum laude
Member Psi Chi, 2002-2004

HONORS & PROFESSIONAL SOCIETIES
Simmons Family Scholarship from 2006-2010 ($8000)
Health Practitioner Military Scholarship (HPSP Scholarship) 2007-2009
Vice-Presidential Fellowship 2005-06 ($15,000)
Travel Award. International Conference on Alzheimer's disease (ICAD), July,
2008, ($600)
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Travel Award. International Neuropsychological Society (INS), October, 2007
($600)
Golden Key National Honor Society

CLINICAL EXPERIENCE

2008- 2009, Student Intern: Bear River Mental Health, Logan, UT
Supervisor: Scott Blickenstaff, Ph.D.
Clinical Population: Adults with severe mental illness. Neuropsychological
assessments on children and adolescents.
Clinical Hours: 325, Total Support Hours: 815
•
•

•

Conducted psychological intakes, psychotherapy, psychological and
neuropsychological assessments.
Served as the sole provider of psychological services for the Cache County
Jail, a 360-bed facility used to house imnates within Cache County, Utah.
Conducted psychological assessments on imnates.
Helped design and implement a Mental Health Court program at the Cache
County Jail. Implemented it in the Spring of 2009. Also designed and helped
write the methods for a Quality Assurance project on the Mental Health Court
program in Cache Valley. Began gathering data in the Surmner of 2009.

2008 - 2009, Behavioral Health Consultant: Cardiac Rehabilitation Center at
Brigham City Community Hospital, Brigham City, UT
Supervisor: M. Scott Deberard, Ph.D.
Clinical Population: Elderly individuals who recently had cardiac surgery or some
other cardiac procedure.
Clinical Hours: 51, Total Support Hours: 115
•
•

Provided psychological assessments and brief psychotherapy for individuals
undergoing cardiac rehabilitation.
Conducted a stress-management group with clients undergoing cardiac
rehabilitation.

2008- 2009, Behavioral Health Consultant: Student Health and Wellness
Center at Utah State University, Logan, UT
Supervisor: M. Scott Deberard, Ph.D.
Clinical Population: Student body attending Utah State University.
Clinical Hours: 24, Total Support Hours: 60
•

Provided short-term individual psychotherapy (4-8 sessions) and
psychological screening in a primary care setting. Conducted intake
interviews and provided referral services to clients requiring more extensive
therapy.
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•
•

Educated clients about topics related to health psychology: chronic pain; stress
management; substance abuse; and sexually transmitted diseases.
Served as consultant to physicians, nurses, and other medical staff regarding
treatment of clients with emotional concerns.

2006 - 2008, Student Intern: Center for Persons with Disabilities at Utah State
University, Logan, UT
Supervisor: Robert C. Cook, Ph.D.
Clinical Population: Children, adolescents and adults with disabilities.
Clinical Hours: 257, Total Support Hours: 640
•

•
•
•

Conducted psycho-educational and neuropsychological evaluations with
children, adolescents, and adults. Present assessment findings in written
reports. Provide evaluation feedback to clients, parents, and school personnel.
Presented clinical cases and provided case conceptualizations for discussion in
multi-disciplinary team meetings.
Consulted with parents and school personnel to create treatment plans to assist
children and adolescents enhance learning and academic performance.
Provided assessments for the specific evaluation of possible Autism or Autism
Spectrum disorders.

2007 - 2008, Student Therapist: Counseling Center at Utah State University, Logan, UT
Supervisor: David Bush, Ph.D.
Clinical Population: Student body attending Utah State University.
Clinical Hours: 104, Total Support Hours: 220
•

•
•

•

Conducted intake interviews and provided brief and long-term
counseling to college students presenting with various DSMAxis I and
Axis II disorders.
Presented clinical cases and led discussions in seminars with a team of
licensed psychologists, psychology interns, and fellow practicum students.
Practiced in a group practicum setting various modes of therapy: Dialectical
Behavioral Therapy; Schema Therapy; Mindfulness; treatment of PTSD,
eating disorders, and addictions.
Delivered outreach presentations on stress management and Counseling
Center resources to university students. Conducted screenings for depression,
anxiety, and alcoholism.

Spring 2006, Student Therapist: Utah State University Psychology Community Clinic.
Logan, UT
Supervisor: Melanie Domenech-Rodriguez Ph.D.
Clinical Hours: 43 Total Support Hours: 110
•

Conducted psychological intakes of students and members of the community
suffering from a variety of psychological disorders.
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•

Conducted long and short-term psychotherapy to adults experiencing various
psychological concerns.

2005-2007, Neuropsychological Technician: Center of Epidemiological Studies, Logan
UT
Supervisor: JoAnn Tschanz, Ph.D.
Clinical Hours: 275, Total Support Hours: 610
•
•
•

Conducted neuropsychological testing on elderly individuals.
Conducted semi-structured interviews with informants of research participants
with normal and impaired cognition.
Participated in review of case material for diagnosing dementia and other
cognition disorders.

RESEARCH EXPERIENCE

2005-present, Research Assistant: Dementia Progression Study and Cache
County Study on Memory in Aging, Logan, UT.
Principal investigator: JoAnn Tschanz, Ph.D.
•
•
•
•

Write and submit research abstracts for scientific conferences.
Conduct literature reviews.
Organize and examine data using SPSS data analysis.
Participate in a multi-disciplinary team comprised of physicians, nurses,
psychologists and graduate students researching the causes and corollaries of
dementia.

2004-2005, Research Assistant: Social Psychology Lab, University of Utah, Salt Lake
City, UT
Principle investigator: Jonathan Butner, Ph.D.
•
•
•

Conducted literature reviews. Created a new dynamic measure for
individualism and collectivism assessment.
Created and managed online mass testing survey questionnaire.
Used factorial analysis to statistically structure new measure for individualism
and collectivism

2003-2004, Research Assistant: Neuropsychology Lab at the University of Utah, Salt
Lake City, UT
Principal investigator: Yana Suchy, Ph.D.
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•

•

Assisted in the creating of a computer device used to assess
neuropsychological deficit in patients who had sustained a traumatic brain
lllJury.
Conducted literature reviews, created computer software used to score
neuropsychological tests, ran research participants on a new measure used to
assess frontal-lobe dysfunction, and examined data.

2003-2004, Research Assistant: Neurobehavioral Lab at the University of Utah, Salt Lake
City, UT
Principal investigator: Raymond Kesner, Ph.D.

•

Conducted hippocampal surgeries on animal subjects (rats). Injected animal
subjects with dopamine agonists and ran subjects on series of complex mazes .

•
•

Conducted data analysis and interpretation.

OTHER PROFESSIONAL EXPERIENCE
2004-2005, Psychiatric Technician: 5 West Psychiatric Unit, University of Utah Hospital,
Salt Lake City, UT

•
•
•

Conducted groups focusing on assisting inpatient psychiatric patients with
interpersonal skills, daily living skills, and stress-management skills.
Monitored and charted patient activities, and met with patients ensure patient
emotional, mental, and physical needs were met.
Met daily in a multi-disciplinary team meeting with physicians, social
workers, and nurses to discuss patient's functional, cognitive, and emotional
concerns.

2001-2004, Medicaid Representative: Department ofNeurology, University of Utah
Hospital, 3rd Floor, Salt Lake City, UT

•
•
•

Assisted low-income patients of neurological and psychiatric units of the
University of Utah Hospital with financial coverage of hospital services.
Provided counseling service and crisis intervention for families following
TBI.
Assisted patients who had undergone a TBI follow through with Medicaid and
SSI disability forms.
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2003-2004, Educational Assistant: The NeuroDevelopment Center, Salt Lake City, UT

•

•

Educated local elementary and junior high school administrative staff in the
presentation and basic intervention skills of seizure activity in children and
adolescents.
Created educational packet, compiled literature and educational material for
administrative personnel of elementary schools in the surrounding Salt Lake
area.

TEACHING EXPERIENCE
Fall, 2009

Teaching Assistantship. Taught one course of Psychology 1730:
Strategies of Academic Success. Undergraduate-level course. Focused on
teaching the reading, test-taking, note-taking, and anxiety management
skills necessary for college success.

Fall, 2008

Teaching Assistant. Psychology 6310, Intellectual Assessment.
Graduate-level course. Assisted graduate students leam to administer and
score standardized intellectual tests. Conducted labs to educate students
on the construct of intelligence, and the viability and utility of its
measurement within the field of psychology.

Spring, 2008 Guest Lecturer: Psychology 1010, Introduction to Psychology. Lectured
on DSM diagnoses, Categorical versus Dimensional approach to
psychiatric diagnoses, and issues regarding the contributory versus
causality factors of psychiatric disorders.
Fall, 2006

Guest Lecturer: Psychology 6310, Intellectual Assessment. Lectured on
the development of the Wechsler Adult and Child intelligence scales, and
on the dominant theories regarding the construct of intelligence.

Spring, 2006 Guest Lecturer: Psychology 1010, Introduction to Psychology. Lectured
on the incidence and prevalence of brain injuries among different
socioeconomic and age groups. Lectured on the impact of traumatic brain
injury (TBI) and cognitive, social, and emotional outcomes.
Fall, 2004

Teaching Assistant. Psychology 3904, Surveys of Clinical Psychology
and Service Learning. Graded assignments and tests regarding the
application and practice within the psychological profession. Lectured on
science and its impact on society, differences between Basic and Applied
Science, and on the fusion between societal values and scientific curiosity.
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OUTREACH/COMMUNITY LECTURE EXPERIENCE
Fall,2008

Clinical Presentation. Presented on the WAIS-IV revision and differences
between the WAIS-IV from the WAIS-III to licensed psychologists and
employees at Bear River Mental Health.

Spring, 2008 Conducted intakes and alcohol screening for students. Provided
appropriate referral sources as necessary.

Spring, 2008 Participated in a free depression-screening for students. Provided
appropriate referral sources as necessary.
Fall, 2007

Guest Presenter: Physical Education, 2020. Co-presented on the services
provided at the Utah State Counseling Center. Presented on self-injurious
behaviors as a coping method for university students.

Fall,2007

Participated in a free anxiety-screening for students. Provided appropriate
referral sources when necessary.

CONFERENCE PRESENTATIONS & ABSTRACTS
Tschanz, J. T., Corcoran, C., Green, H., Munger, R., Mielke, M., Norton, M., Rabins, P.,
Welsh-Bohmer, K., Buckley, T., Breitner, J., Lyketsos, M. (January, 2009). Interaction
between C-Reactive Protein level and APOE genotype in predicting rate of progression
in Alzheimer's disease. The Cache County Dementia Progression Study. Presentation at
the International Conference on Alzheimer's Disease (ICAD) in Vienna, Austria.
Morrison, A., Buckley, T., Piercy, K., Norton, M., Rabins, P., Tschanz, J., Lyketsos, C.
(February, 2009). Predictors of Quality of Life Ratings for Persons with Dementia
Simultaneously Reported by Patients and their Caregivers: The Cache County (Utah)
Study. Presentation at the Conference of the Southern Nursing Research Society (SNRS),
Baltimore, Maryland.
Buckley, T., Norton, M., Deberard, M.S., Welsh-Bohmer, K., Lyketsos, C., Tschanz, J.
(July, 2008). Assessment of awareness of cognitive change in individuals with and
without dementia: The Cache County Study. Poster session presented at the International
Conference on Alzheimer's disease (ICAD), Chicago, Illinois.
Tschanz, J., Cook, L., Corcoran, C., Norton, M., Mielke, M., Rabins, P., Welsh-Bohmer,
K.A., Treiber, K., Buckley, T., Breitner, J.C.S., Lyketsos, C. Gender Differences in the
Trajectory of Cognitive Decline in Alzheimer's Disease in the Cache County Population.
Presentation at the 36th Annual Meeting of the International Neuropsychological Society,
Waikola, Hawaii, Feb., 2008.
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Buckley, T., Tschanz, J., Norton, M., Corcoran, C., Welsh-Bohmer, K., Breitner, J.,
(September, 2007). Metacognitive Judgments and Change in Cognitive and Functional
Abilities in a Population of Elderly Individuals. The Cache County Study. Poster session
presented at the International Neuropsychological Society (INS) Conference, Portland,
Oregon.
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County Population. Poster session presented at the International Neuropsychology
Conference (INS) Po1tland, Oregon.
Tschanz J., Cook L., Corcoran C., Norton M., Mielke M., Rosenberg, P., Buckley T.,
Clay, C., Welsh-Bohmer, K., Breitner, J., Lyketsos, C. (August, 2006). Vascular Factors
and the Rate of Decline in Dementia; The Cache County Study. Presentation at the
International Conference on Alzheimer's Disease (ICAD) in Madrid, Spain.

PEER-REVIEWED PUBLICATIONS:
Buckley, T., Norton, M., Deberard, M., Welsh-Bohmer, Lyketsos, C., Tschanz, J.T.
(2009). A BriefMetacognition Questionnaire for the Elderly: Comparison with Cognitive
Performance and Informant Ratings: The Cache County Study. International Journal of
Geriatric Psychiatry, in press.

PRINTED DISPATCH
Buckley, T., Tschanz, J.T. (2008). Anosognosia: Assessment Tools for Its Epidemiologic
Study in Geriatric Populations with Dementia, Primary Psychiatry, 9, 24-29.

PROFESSIONAL AFFILIATIONS
American Psychological Association, Student Affiliate

PROFESSIONAL DEVELOPMENT
04/2009

Attendee, Psychology Department at Utah State University training
seminar, Logan, UT.
Acceptance and Commitment Therapy (ACT). Full day seminar on ACT.
Presented by Dr. Steven Hayes, co-founder of ACT.
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10/2008

Attendee, Bear River Mental Health Training Seminar, Logan, UT.
Brain Games: New Avenues in Brain Rehabilitation: Full day seminar
that introduced therapeutic training techniques for individuals in the
neurological rehabilitation process following a TBI. Presented by NancyLouise Howse, Ph.D.

09/2008

Attendee, Utah Psychological Association Training Seminar, Salt Lake
City, UT.
WAIS-IV Update: 3-hour seminar on the new version of the Wechsler
Adult Intelligence Scales. Presented by Patrick J. Moran, Ph.D., The
Psychological Corporation.

04/2008

Attendee, 14th Annual Utah State University Counseling Center
Conference, Logan, UT.
Mindfulness-Based Cognitive Therapy: I-day workshop on the use of
mindfulness in cognitive behavioral psychotherapy. Presented by Mark
Lau, Ph.D., University of British Columbia.

02/2007

Attendee, Utah State University Center for Epidemiological Studies
Seminar, Logan, UT.
Epidemiology of Alzheimer's Disease: 2-hour seminar on the etiology of
Alzheimer's disease and current pharmaceutical treatments. Presented by
Constantine Lyketsos, M.D., MPH, Johns Hopkins University.

09/2006

Attendee, Utah State University Center for Persons with Disabilities
Seminar, Logan, UT.
Traumatic Brain Injury and Rehabilitation: 1-day multidisciplinary
seminar on traumatic brain injury and techniques/resources for working
with survivors and their families, presented by the Interdisciplinary
Training unit at the Center for Persons with Disabilities. Presented by:
David Nilsson, Ph.D.

05/2006

Participant, Workshop in Dementia Research, Provo, UT.
Rating System for MRI Images: 4-hour workshop on a system for rating
brain scans of participants in the Cache County Study on Memory, Health,
and Aging. Presented by Erin Bigler, Ph.D., Brigham Young University.
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